200,000+ products from a single source!
sales@angenechem.com
625-85-4 | 2,4-DIHYDROXYTHIAZOLE
CAS No: 625-85-4 Catalog No: AG00EBXV MDL No:
Product Description
Catalog Number:
AG00EBXV
Chemical Name:
2,4-DIHYDROXYTHIAZOLE
CAS Number:
625-85-4
IUPAC Name:
4-hydroxy-3H-1,3-thiazol-2-one
InChI:
InChI=1S/C3H3NO2S/c5-2-1-7-3(6)4-2/h1,5H,(H,4,6)
InChI Key:
MQYUOKQDHLEQAC-UHFFFAOYSA-N
Properties
Complexity:
131
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
116.988g/mol
Formal Charge:
0
Heavy Atom Count:
7
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
117.122g/mol
Monoisotopic Mass:
116.988g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
74.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.1
Literature
| Title | Journal |
|---|---|
| Rosiglitazone shows partial oncostatic effect in rat mammary carcinogenesis. | Neoplasma 20130101 |
| Pioglitazone in clinical practice: where are we now? | Diabetes therapy : research, treatment and education of diabetes and related disorders 20121201 |
| A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus. | Diabetes, obesity & metabolism 20121101 |
| Density functional study on the cytochrome-mediated S-oxidation: identification of crucial reactive intermediate on the metabolic path of thiazolidinediones. | The journal of physical chemistry. A 20121025 |
| Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin-treated mouse models. | Neuroscience letters 20121018 |
| Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. | Toxicology letters 20121002 |
| Pharmacokinetics of pioglitazone in lean and obese cats. | Journal of veterinary pharmacology and therapeutics 20121001 |
| A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. | Clinical lymphoma, myeloma & leukemia 20121001 |
| Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists. | European journal of medicinal chemistry 20121001 |
| Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. | Clinical therapeutics 20121001 |
| Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. | Journal of the National Cancer Institute 20120919 |
| Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C). | Bioorganic & medicinal chemistry letters 20120915 |
| Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record. | Pharmacoepidemiology and drug safety 20120901 |
| Selective block of K(ATP) channels: why the anti-diabetic sulphonylureas and rosiglitazone have more in common than we thought. | British journal of pharmacology 20120901 |
| PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. | Journal of lipid research 20120901 |
| Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists. | Medicinal chemistry (Shariqah (United Arab Emirates)) 20120901 |
| A peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4. | Toxicology and applied pharmacology 20120901 |
| Adiponectin and all-cause mortality in elderly people with type 2 diabetes. | Diabetes care 20120901 |
| Urea/thiourea catalyzed, solvent-free synthesis of 5-arylidenethiazolidine-2,4-diones and 5-arylidene-2-thioxothiazolidin-4-ones. | Bioorganic & medicinal chemistry letters 20120901 |
| GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. | The Journal of biological chemistry 20120810 |
| Protective effect of pharmacologic preconditioning with pioglitazone on random-pattern skin flap in rat is mediated by nitric oxide system. | The Journal of surgical research 20120801 |
| Increased marrow adiposity in premenopausal women with idiopathic osteoporosis. | The Journal of clinical endocrinology and metabolism 20120801 |
| Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease. | Coronary artery disease 20120801 |
| Effect of pioglitazone on transdifferentiation of preosteoblasts from rat bone mesenchymal stem cells into adipocytes. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20120801 |
| Rosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells. | American journal of physiology. Cell physiology 20120715 |
| Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. | Archives of internal medicine 20120709 |
| Thiazolidinediones and macular edema: comment on 'Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes'. | Archives of internal medicine 20120709 |
| Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts. | Pharmacogenetics and genomics 20120701 |
| Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. | Diabetes care 20120701 |
| Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry. | Diabetes research and clinical practice 20120701 |
| Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring. | European journal of medicinal chemistry 20120701 |
| Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. | Expert opinion on drug discovery 20120701 |
| Thiazolidinedione safety. | Expert opinion on drug safety 20120701 |
| Geographic variation in pharmacotherapy decisions for U.S. Medicare enrollees with diabetes. | Journal of diabetes and its complications 20120701 |
| The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. | Atherosclerosis 20120701 |
| PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. | Nature 20120628 |
| Data-driven integration of epidemiological and toxicological data to select candidate interacting genes and environmental factors in association with disease. | Bioinformatics (Oxford, England) 20120615 |
| Algicidal activity of thiazolidinedione derivatives against harmful algal blooming species. | Marine biotechnology (New York, N.Y.) 20120601 |
| Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. | European journal of endocrinology 20120601 |
| Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. | Cardiovascular drugs and therapy 20120601 |
| Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. | Diabetologia 20120601 |
| Risk of fracture with thiazolidinediones: disease or drugs? | Calcified tissue international 20120601 |
| Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? | Annals of medicine 20120601 |
| Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation. | Experimental & molecular medicine 20120531 |
| A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. | Nature 20120517 |
| Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors. | Bioorganic & medicinal chemistry 20120515 |
| Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. | Diabetes, obesity & metabolism 20120501 |
| Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology. | American journal of physiology. Endocrinology and metabolism 20120501 |
| Development of a novel class of glucose transporter inhibitors. | Journal of medicinal chemistry 20120426 |
| 5-benzylidenerhodanine and 5-benzylidene-2-4-thiazolidinedione based antibacterials. | Bioorganic & medicinal chemistry letters 20120415 |
| NADPH inhibits [2Fe-2S] cluster protein transfer from diabetes drug target MitoNEET to an apo-acceptor protein. | The Journal of biological chemistry 20120406 |
| Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c. | Primary care diabetes 20120401 |
| DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. | Diabetes & metabolism 20120401 |
| Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea. | Diabetes & metabolism journal 20120401 |
| The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells. | Gut and liver 20120401 |
| Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies. | Annals of medicine 20120301 |
| Peroxisome proliferating activating receptor gamma-independent attenuation of interleukin 6 and interleukin 8 secretion from primary endometrial stromal cells by thiazolidinediones. | Fertility and sterility 20120301 |
| Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue. | Endocrinology 20120301 |
| Design and synthesis of 5-(substituted benzylidene)thiazolidine-2,4-dione derivatives as novel tyrosinase inhibitors. | European journal of medicinal chemistry 20120301 |
| Thiazolidinedione treatment decreases oxidative stress in spontaneously hypertensive heart failure rats through attenuation of inducible nitric oxide synthase-mediated lipid radical formation. | Diabetes 20120301 |
| Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications. | The Annals of pharmacotherapy 20120301 |
| The role of insulin resistance in the development of muscle wasting during cancer cachexia. | Journal of cachexia, sarcopenia and muscle 20120301 |
| Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. | Journal of applied toxicology : JAT 20120201 |
| Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. | Journal of affective disorders 20120201 |
| A scaffold hopping approach to identify novel monoamine oxidase B inhibitors. | Bioorganic & medicinal chemistry letters 20120201 |
| Methyl (2E)-2-[(2,4-dioxo-1,3-thia-zolidin-3-yl)meth-yl]-3-phenyl-prop-2-enoate. | Acta crystallographica. Section E, Structure reports online 20120201 |
| Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. | Drugs 20120122 |
| Effects of the insulin sensitizing drug, pioglitazone, and lipopolysaccharide administration on markers of systemic inflammation and clinical parameters in horses. | Veterinary immunology and immunopathology 20120115 |
| An alternative synthetic route for an antidiabetic drug, rosiglitazone. | Bioorganic & medicinal chemistry letters 20120115 |
| Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. | The Journal of biological chemistry 20120102 |
| The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria. | PPAR research 20120101 |
| Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. | Diabetes, obesity & metabolism 20120101 |
| Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. | International journal of vascular medicine 20120101 |
| PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. | Neurobiology of disease 20120101 |
| Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. | Diabetologia 20120101 |
| 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. | European journal of medicinal chemistry 20120101 |
| Regulation of LYRM1 gene expression by free fatty acids, adipokines, and rosiglitazone in 3T3-L1 adipocytes. | Experimental diabetes research 20120101 |
| Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties. | Bioorganic & medicinal chemistry letters 20120101 |
| In vivo adipogenesis in rats measured by cell kinetics in adipocytes and plastic-adherent stroma-vascular cells in response to high-fat diet and thiazolidinedione. | Diabetes 20120101 |
| Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors. | Bioorganic & medicinal chemistry letters 20120101 |
| Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico. | International journal of clinical pharmacology and therapeutics 20120101 |
| The role of metformin in the management of NAFLD. | Experimental diabetes research 20120101 |
| IVSPlat 1.0: an integrated virtual screening platform with a molecular graphical interface. | Chemistry Central journal 20120101 |
| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. | BMJ (Clinical research ed.) 20120101 |
| Using hydrophilic ionic liquid, [bmim]BF4-ethylene glycol system as a novel media for the rapid synthesis of copper nanoparticles. | PloS one 20120101 |
| Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. | Cardiovascular diabetology 20120101 |
| Methyl (Z)-2-[(2,4-dioxothia-zolidin-3-yl)meth-yl]-3-(2-methyl-phen-yl)prop-2-enoate. | Acta crystallographica. Section E, Structure reports online 20120101 |
| Preventive pharmacotherapy in type 2 diabetes mellitus. | Indian journal of endocrinology and metabolism 20120101 |
| High prevalence of gastroesophageal reflux symptoms in type 2 diabetics with hypoadiponectinemia and metabolic syndrome. | Nutrition & metabolism 20120101 |
| Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma. | Chemistry Central journal 20120101 |
| Mammalian ste20-like kinase and SAV1 promote 3T3-L1 adipocyte differentiation by activation of PPARγ. | PloS one 20120101 |
| AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. | Journal of managed care pharmacy : JMCP 20120101 |
| Periodic 48 h feed withdrawal improves glucose tolerance in growing pigs by enhancing adipogenesis and lipogenesis. | Nutrition & metabolism 20120101 |
| Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. | Nutrition & metabolism 20120101 |
| Microglia function in Alzheimer's disease. | Frontiers in pharmacology 20120101 |
| Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. | Gut and liver 20120101 |
| (+)-Rutamarin as a dual inducer of both GLUT4 translocation and expression efficiently ameliorates glucose homeostasis in insulin-resistant mice. | PloS one 20120101 |
| Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. | Diabetology & metabolic syndrome 20120101 |
| Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. | PloS one 20120101 |
| Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells. | Cardiovascular diabetology 20120101 |
| Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101 |
| The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes. | PPAR research 20120101 |
| Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy. | PPAR research 20120101 |
| The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells. | PPAR research 20120101 |
| Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. | PloS one 20120101 |
| The influence of incretin mimetics on cardiovascular risk factors in diabetes. | ISRN endocrinology 20120101 |
| The diabetic heart: too sweet for its own good? | Cardiology research and practice 20120101 |
| Effects of Extract from Solid-State Fermented Cordyceps sinensis on Type 2 Diabetes Mellitus. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Resistance Training in Type II Diabetes Mellitus: Impact on Areas of Metabolic Dysfunction in Skeletal Muscle and Potential Impact on Bone. | Journal of nutrition and metabolism 20120101 |
| Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. | PloS one 20120101 |
| Insulin in central nervous system: more than just a peripheral hormone. | Journal of aging research 20120101 |
| Oxidative stress and heme oxygenase-1 regulated human mesenchymal stem cells differentiation. | International journal of hypertension 20120101 |
| Regulation of chemokine and chemokine receptor expression by PPARγ in adipocytes and macrophages. | PloS one 20120101 |
| Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. | International journal of general medicine 20120101 |
| Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. | Theranostics 20120101 |
| Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. | PloS one 20120101 |
| Pilot study of an individualised early postpartum intervention to increase physical activity in women with previous gestational diabetes. | International journal of endocrinology 20120101 |
| The modulation of PPARγ1 and PPARγ2 mRNA expression by ciglitazone in CD3/CD28-activated naïve and memory CD4+ T cells. | Clinical & developmental immunology 20120101 |
| Uncovering undetected hypoglycemic events. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
| Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. | International journal of vascular medicine 20120101 |
| Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. | Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20120101 |
| Low affinity GPCRs for metabolic intermediates: challenges for pharmacologists. | Frontiers in endocrinology 20120101 |
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. | BMJ (Clinical research ed.) 20120101 |
| PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. | PPAR research 20120101 |
| Comparison of different blood pressure indices for the prediction of prevalent diabetic nephropathy in a sub-Saharan African population with type 2 diabetes. | The Pan African medical journal 20120101 |
| Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. | Experimental diabetes research 20120101 |
| Effects of PPARγ Ligands on Leukemia. | PPAR research 20120101 |
| The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists. | PPAR research 20120101 |
| Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. | Core evidence 20120101 |
| Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats. | Indian journal of pharmacology 20120101 |
| Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes. | Indian journal of pharmacology 20120101 |
| Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. | Experimental diabetes research 20120101 |
| Ficus deltoidea: A Potential Alternative Medicine for Diabetes Mellitus. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Hypoglycemic agent screening by LC-MS/MS. | Methods in molecular biology (Clifton, N.J.) 20120101 |
| Insulin resistance in patients with chronic kidney disease. | Journal of biomedicine & biotechnology 20120101 |
| Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. | PPAR research 20120101 |
| New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. | Bioorganic & medicinal chemistry 20111215 |
| Combined transcriptomic-(1)H NMR metabonomic study reveals that monoethylhexyl phthalate stimulates adipogenesis and glyceroneogenesis in human adipocytes. | Journal of proteome research 20111202 |
| Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-κB activation and endoplasmic reticulum stress-induced cell death. | Journal of cellular physiology 20111201 |
| 15-deoxy-Δ(12,14) -prostaglandin-J2 and ciglitazone inhibit TNF-α-induced matrix metalloproteinase 13 production via the antagonism of NF-κB activation in human synovial fibroblasts. | Journal of cellular physiology 20111201 |
| Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. | Annals of oncology : official journal of the European Society for Medical Oncology 20111201 |
| Metabolic effects of pioglitazone in chemically-induced mammary carcinogenesis in rats. | Pathology oncology research : POR 20111201 |
| The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications. | Endocrine, metabolic & immune disorders drug targets 20111201 |
| Effects of raising muscle glycogen synthesis rate on skeletal muscle ATP turnover rate in type 2 diabetes. | American journal of physiology. Endocrinology and metabolism 20111201 |
| Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells. | Experimental and molecular pathology 20111201 |
| Comparison of the acute toxicities of novel algicides, thiazolidinedione derivatives TD49 and TD53, to various marine organisms. | Environmental toxicology and chemistry 20111201 |
| Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes. | Pharmacogenetics and genomics 20111201 |
| Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells. | Toxicology in vitro : an international journal published in association with BIBRA 20111201 |
| Solvent-free, microwave assisted Knoevenagel condensation of novel 2,5-disubstituted indole analogues and their biological evaluation. | European journal of medicinal chemistry 20111201 |
| Synthesis and biological evaluation of novel dimethyl[1,1'-biphenyl]-2,2'-dicarboxylate derivatives containing thiazolidine-2,4-dione for the treatment of concanavalin A-induced acute liver injury of BALB/c mice. | European journal of medicinal chemistry 20111201 |
| Effects of plane of nutrition and 2,4-thiazolidinedione on insulin responses and adipose tissue gene expression in dairy cattle during late gestation. | Journal of dairy science 20111201 |
| Metformin: multi-faceted protection against cancer. | Oncotarget 20111201 |
| Study on the effects of intermolecular interactions on firefly multicolor bioluminescence. | Chemphyschem : a European journal of chemical physics and physical chemistry 20111118 |
| Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. | Diabetes, obesity & metabolism 20111101 |
| Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. | Diabetes, obesity & metabolism 20111101 |
| Opposing actions of rosiglitazone and resveratrol on mineralization in human vascular smooth muscle cells. | Journal of molecular and cellular cardiology 20111101 |
| New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation. | European journal of medicinal chemistry 20111101 |
| Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study. | Clinical therapeutics 20111101 |
| Effects of prepartum 2,4-thiazolidinedione on insulin sensitivity, plasma concentrations of tumor necrosis factor-α and leptin, and adipose tissue gene expression. | Journal of dairy science 20111101 |
| Overlapping medication associated with healthcare switching among Korean elderly diabetic patients. | Journal of Korean medical science 20111101 |
| Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. | Current drug safety 20111101 |
| Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. | Breast cancer research and treatment 20111001 |
| The Monascus metabolite monascin against TNF-α-induced insulin resistance via suppressing PPAR-γ phosphorylation in C2C12 myotubes. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20111001 |
| Fixed dose combination diabetes medicines - usage in the Australian veteran population. | Australian family physician 20111001 |
| Global mapping of cell type-specific open chromatin by FAIRE-seq reveals the regulatory role of the NFI family in adipocyte differentiation. | PLoS genetics 20111001 |
| Glucolipotoxicity in Pancreatic β-Cells. | Diabetes & metabolism journal 20111001 |
| Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. | Diabetes & metabolism journal 20111001 |
| Interaction of cinnamic acid derivatives with commercial hypoglycemic drugs on 2-deoxyglucose uptake in 3T3-L1 adipocytes. | Journal of agricultural and food chemistry 20110928 |
| Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. | Nature 20110922 |
| A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET. | Bioorganic & medicinal chemistry letters 20110915 |
| A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. | Diabetes, obesity & metabolism 20110901 |
| In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction. | European journal of drug metabolism and pharmacokinetics 20110901 |
| Add-on rosiglitazone therapy improves plasminogen activity and high-density lipoprotein cholesterol in type 2 diabetes mellitus. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20110901 |
| Anti-stroke profile of thiazolidin-4-one derivatives in focal cerebral ischemia model in rat. | Chemical biology & drug design 20110901 |
| The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. | Biochimica et biophysica acta 20110901 |
| Novel 2-thioxothiazolidin-4-one inhibitors of bacterial MurD ligase targeting D-Glu- and diphosphate-binding sites. | European journal of medicinal chemistry 20110901 |
| Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes. | Annales d'endocrinologie 20110901 |
| Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
| 5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion. | Experimental & molecular medicine 20110831 |
| Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist. | The Biochemical journal 20110815 |
| Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B. | Bioorganic & medicinal chemistry letters 20110815 |
| Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. | Circulation 20110809 |
| Role of nuclear receptor corepressor RIP140 in metabolic syndrome. | Biochimica et biophysica acta 20110801 |
| PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. | Biochimica et biophysica acta 20110801 |
| Synthesis of new chalcone derivatives bearing 2,4-thiazolidinedione and benzoic acid moieties as potential anti-bacterial agents. | European journal of medicinal chemistry 20110801 |
| Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. | Clinical therapeutics 20110801 |
| PPARγ population shift produces disease-related changes in molecular networks associated with metabolic syndrome. | Cell death & disease 20110801 |
| Response: the effect of an Angiotensin receptor blocker on arterial stiffness in type 2 diabetes mellitus patients with hypertension (diabetes metab j 2011;35:236-42). | Diabetes & metabolism journal 20110801 |
| High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. | Chemistry & biology 20110729 |
| Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors. | Journal of medicinal chemistry 20110728 |
| Structure-based design of novel boronic acid-based inhibitors of autotaxin. | Journal of medicinal chemistry 20110714 |
| Thiazolidinediones regulate adipose lineage dynamics. | Cell metabolism 20110706 |
| Engineered heart tissue model of diabetic myocardium. | Tissue engineering. Part A 20110701 |
| Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. | Diabetes research and clinical practice 20110701 |
| In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. | Drug metabolism and disposition: the biological fate of chemicals 20110701 |
| Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. | Expert opinion on pharmacotherapy 20110701 |
| Thiazolidinediones and fracture risk in patients with Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20110701 |
| Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. | Postgraduate medicine 20110701 |
| Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. | Diabetes care 20110701 |
| Bromocriptine in type 2 diabetes mellitus. | Indian journal of endocrinology and metabolism 20110701 |
| Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. | Chemico-biological interactions 20110630 |
| Complexes of the outer mitochondrial membrane protein mitoNEET with resveratrol-3-sulfate. | Biochemistry 20110628 |
| Lipophilicity as a determinant of thiazolidinedione action in vitro: findings from BLX-1002, a novel compound without affinity to PPARs. | American journal of physiology. Cell physiology 20110601 |
| Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. | Molecular pharmacology 20110601 |
| DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. | Diabetic medicine : a journal of the British Diabetic Association 20110601 |
| Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. | Journal of veterinary pharmacology and therapeutics 20110601 |
| Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. | Diabetes care 20110601 |
| Novel ligands that target the mitochondrial membrane protein mitoNEET. | Journal of molecular graphics & modelling 20110601 |
| The effect of an Angiotensin receptor blocker on arterial stiffness in type 2 diabetes mellitus patients with hypertension. | Diabetes & metabolism journal 20110601 |
| Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration. | Diabetes & metabolism journal 20110601 |
| Letter: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65). | Diabetes & metabolism journal 20110601 |
| Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-α and interleukin-6 in patients with polycystic ovary syndrome. | Clinical and experimental reproductive medicine 20110601 |
| Synthesis of spirocyclic thiazolidinediones using ring-closing metathesis and one-pot sequential ring-closing/cross metathesis. | Organic & biomolecular chemistry 20110521 |
| Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. | Thorax 20110501 |
| Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. | Current medical research and opinion 20110501 |
| Peroxisome proliferator-activated receptor-γ stimulates 11β-hydroxysteroid dehydrogenase type 1 in rat vascular smooth muscle cells. | Steroids 20110501 |
| Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure. | Circulation. Heart failure 20110501 |
| Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. | Diabetes care 20110501 |
| Diabetes as a cause of clinically significant functional cobalamin deficiency. | Diabetes care 20110501 |
| Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning. | International journal of clinical practice 20110501 |
| [Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases]. | Clinical calcium 20110501 |
| A role for central nervous system PPAR-γ in the regulation of energy balance. | Nature medicine 20110501 |
| [A compounding agent of alogliptin and pioglitazone]. | Nihon rinsho. Japanese journal of clinical medicine 20110501 |
| rac-tert-Butyl 2-{5-[(4-{2-[methyl(pyri-din-2-yl)amino]ethoxy}phenyl)methyl]-2,4-dioxo-1,3-thiazolidin-3-yl}acetate. | Acta crystallographica. Section E, Structure reports online 20110501 |
| Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501 |
| Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110501 |
| Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases. | Journal of medicinal chemistry 20110414 |
| Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys. | Drug metabolism and disposition: the biological fate of chemicals 20110401 |
| Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20110401 |
| Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. | Arteriosclerosis, thrombosis, and vascular biology 20110401 |
| Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. | Analytical and bioanalytical chemistry 20110401 |
| Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure. | Pharmacoepidemiology and drug safety 20110401 |
| Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. | Diabetes care 20110401 |
| Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice. | Diabetes 20110401 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20110401 |
| Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. | Diabetes care 20110401 |
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Diabetes care 20110401 |
| Cohort study of pioglitazone and cancer incidence in patients with diabetes. | Diabetes care 20110401 |
| Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. | Diabetes & vascular disease research 20110401 |
| Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success. | Clinical therapeutics 20110401 |
| Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity. | Diabetes & metabolism journal 20110401 |
| Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins. | Molecules and cells 20110331 |
| Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone. | Toxicology letters 20110305 |
| Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data. | Inflammatory bowel diseases 20110301 |
| Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. | Diabetes, obesity & metabolism 20110301 |
| Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. | Diabetes 20110301 |
| Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. | Diabetes 20110301 |
| Metformin or thiazolidinedione therapy in PCOS? | Nature reviews. Endocrinology 20110301 |
| Visceral fat accumulation is associated with circadian blood pressure in Japanese patients with impaired glucose tolerance. | Diabetes care 20110301 |
| Gastric peroxisome proliferator activator receptor-γ expression and cytoprotective actions of its ligands against ischemia-reperfusion injury in rats. | Journal of clinical biochemistry and nutrition 20110301 |
| Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis. | JACC. Cardiovascular interventions 20110301 |
| PPARγ agonist beyond glucose lowering effect. | The Korean journal of internal medicine 20110301 |
| Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population. | Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110301 |
| Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110301 |
| S-oxidation of thiazolidinedione with hydrogen peroxide, peroxynitrous acid, and C4a-hydroperoxyflavin: a theoretical study. | The journal of physical chemistry. A 20110210 |
| Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110201 |
| Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. | Journal of molecular endocrinology 20110201 |
| Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. | Current atherosclerosis reports 20110201 |
| Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. | Diabetes, obesity & metabolism 20110201 |
| Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. | Diabetes care 20110201 |
| Distribution of abdominal visceral and subcutaneous adipose tissue and metabolic syndrome in a Korean population. | Diabetes care 20110201 |
| Type 2 diabetes: uses of thiazolidinediones and insulin. | Diabetes care 20110201 |
| The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. | Diabetes care 20110201 |
| A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma. | Diabetes 20110201 |
| Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. | Diabetes & metabolism journal 20110201 |
| Insulin signaling and insulin sensitizing in muscle and liver of obese monkeys: peroxisome proliferator-activated receptor gamma agonist improves defective activation of atypical protein kinase C. | Antioxidants & redox signaling 20110115 |
| A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists. | ChemMedChem 20110103 |
| A Chinese Herbal Decoction, Dang Gui Bu Xue Tang, Prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates Insulin Resistance Induced by A High-Fructose Diet in Rats. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Free radical scavenging abilities of flavonyl-thiazolidine-2,4-dione compounds. | Luminescence : the journal of biological and chemical luminescence 20110101 |
| Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. | Cell death and differentiation 20110101 |
| Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. | Journal of diabetes and its complications 20110101 |
| Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells. | Journal of natural medicines 20110101 |
| Weight considerations in pharmacotherapy for type 2 diabetes. | Journal of obesity 20110101 |
| Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. | Diabetes care 20110101 |
| Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules. | Journal of biomedicine & biotechnology 20110101 |
| FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction. | Diabetes 20110101 |
| Interaction study of pioglitazone with albumin by fluorescence spectroscopy and molecular docking. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110101 |
| Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Lipid-induced insulin resistance affects women less than men and is not accompanied by inflammation or impaired proximal insulin signaling. | Diabetes 20110101 |
| Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells. | Oncology reports 20110101 |
| The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: a retrospective cohort. | Pharmacoepidemiology and drug safety 20110101 |
| The American Diabetes Association's 57th annual advanced postgraduate course: diabetes risk, vitamin D, polycystic ovary syndrome, and obstructive sleep apnea. | Diabetes care 20110101 |
| Executive summary: standards of medical care in diabetes--2011. | Diabetes care 20110101 |
| Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. | BMC cancer 20110101 |
| Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models. | PloS one 20110101 |
| Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. | BMC gastroenterology 20110101 |
| Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. | Cardiovascular diabetology 20110101 |
| Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists. | Journal of obesity 20110101 |
| Pharmacological and non-pharmacological interventions to influence adipose tissue function. | Cardiovascular diabetology 20110101 |
| Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. | PloS one 20110101 |
| Adiponectin levels and expression of adiponectin receptors in isolated monocytes from overweight patients with coronary artery disease. | Cardiovascular diabetology 20110101 |
| The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. | Cardiovascular diabetology 20110101 |
| Regulation of brown fat adipogenesis by protein tyrosine phosphatase 1B. | PloS one 20110101 |
| Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. | PloS one 20110101 |
| Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study. | Cardiovascular diabetology 20110101 |
| Metformin: the safest hypoglycaemic agent in chronic kidney disease? | Nephron. Clinical practice 20110101 |
| The endotoxin-induced neuroinflammation model of Parkinson's disease. | Parkinson's disease 20110101 |
| Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. | Cardiovascular diabetology 20110101 |
| Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. | BMJ (Clinical research ed.) 20110101 |
| Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. | Vascular health and risk management 20110101 |
| Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. | Journal of medical case reports 20110101 |
| Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. | International journal of biological sciences 20110101 |
| Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Inherited destiny? Genetics and gestational diabetes mellitus. | Genome medicine 20110101 |
| Metabolic syndrome and renal injury. | Cardiology research and practice 20110101 |
| Regulation of Serum Response Factor and Adiponectin by PPARγ Agonist Docosahexaenoic Acid. | Journal of lipids 20110101 |
| Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community. | Cardiovascular diabetology 20110101 |
| Rosiglitazone quantification in rat plasma using high performance liquid chromatography with mass spectrometric detection and its application to pre-clinical pharmacokinetic studies. | PDA journal of pharmaceutical science and technology 20110101 |
| 5-(4-Hy-droxy-3-meth-oxy-benz-yl)-1,3-thia-zolidine-2,4-dione monohydrate. | Acta crystallographica. Section E, Structure reports online 20110101 |
| Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. | BMC endocrine disorders 20110101 |
| Lysophosphatidic acid activates peroxisome proliferator activated receptor-γ in CHO cells that over-express glycerol 3-phosphate acyltransferase-1. | PloS one 20110101 |
| Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. | PloS one 20110101 |
| Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101 |
| Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance. | Pathology research international 20110101 |
| Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. | Cell communication and signaling : CCS 20110101 |
| Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. | Indian journal of endocrinology and metabolism 20110101 |
| Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. | Experimental diabetes research 20110101 |
| Clinical review: adiponectin biology and its role in inflammation and critical illness. | Critical care (London, England) 20110101 |
| Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. | Cardiovascular diabetology 20110101 |
| Ghrelin Protects against the Detrimental Consequences of Porphyromonas gingivalis-Induced Akt Inactivation through S-Nitrosylation on Salivary Mucin Synthesis. | International journal of inflammation 20110101 |
| Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? | Parkinson's disease 20110101 |
| HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells. | Retrovirology 20110101 |
| The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. | BMC endocrine disorders 20110101 |
| Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPARγ2 expression in MSCs-like of osteoporotic patients. | PloS one 20110101 |
| Pleiotropic effects of glitazones: a double edge sword? | Frontiers in pharmacology 20110101 |
| Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. | Reproductive biology and endocrinology : RB&E 20110101 |
| The mechanisms by which lipids coordinately regulate the formation of the protein and lipid domains of the stratum corneum: Role of fatty acids, oxysterols, cholesterol sulfate and ceramides as signaling molecules. | Dermato-endocrinology 20110101 |
| Synthesis of tryptoline-3-carboxylic Acid derivatives a novel antidiabetic agent. | Journal of young pharmacists : JYP 20110101 |
| Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures. | BMC endocrine disorders 20110101 |
| From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy. | Experimental diabetes research 20110101 |
| Adipose tissue remodeling as homeostatic inflammation. | International journal of inflammation 20110101 |
| Electrophilic PPARγ Ligands Attenuate IL-1β and Silica-Induced Inflammatory Mediator Production in Human Lung Fibroblasts via a PPARγ-Independent Mechanism. | PPAR research 20110101 |
| Epigenetic regulation of mesenchymal stem cells: a focus on osteogenic and adipogenic differentiation. | Stem cells international 20110101 |
| AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. | PloS one 20110101 |
| Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Is obesity in women protective against osteoporosis? | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
| Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease. | PPAR research 20110101 |
| Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. | PloS one 20110101 |
| State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). | International journal of pediatric endocrinology 20110101 |
| Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ. | PloS one 20110101 |
| Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. | Current gerontology and geriatrics research 20110101 |
| Type 2 diabetes is associated with altered NF-κB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS. | PloS one 20110101 |
| Carbon-nanoparticle-triggered acute lung inflammation and its resolution are not altered in PPARγ-defective (P465L) mice. | Particle and fibre toxicology 20110101 |
| Differential gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenic development. | BMC genomics 20110101 |
| Structure and molecular evolution of CDGSH iron-sulfur domains. | PloS one 20110101 |
| A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. | Health and quality of life outcomes 20110101 |
| Differentiation potential of pancreatic fibroblastoid cells/stellate cells: effects of peroxisome proliferator-activated receptor gamma ligands. | International journal of cell biology 20110101 |
| High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity. | International journal of molecular sciences 20110101 |
| Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| Pioglitazone: Indian perspective. | Indian journal of endocrinology and metabolism 20110101 |
| Choosing a gliptin. | Indian journal of endocrinology and metabolism 20110101 |
| Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome. | Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101 |
| Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. | Open medicine : a peer-reviewed, independent, open-access journal 20110101 |
| Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone. | PloS one 20110101 |
| Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet. | PloS one 20110101 |
| Investigation of the antibacterial activity of pioglitazone. | Drug design, development and therapy 20110101 |
| Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population. | Neuropsychiatric disease and treatment 20110101 |
| Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. | Diabetology & metabolic syndrome 20110101 |
| Lipid chaperones and metabolic inflammation. | International journal of inflammation 20110101 |
| Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System. | Journal of oncology 20110101 |
| Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. | Cardiovascular diabetology 20110101 |
| Molecular determinants of magnolol targeting both RXRα and PPARγ. | PloS one 20110101 |
| Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. | PloS one 20110101 |
| A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugates. | Scientia pharmaceutica 20110101 |
| Rosiglitazone and fenofibrate additive effects on lipids. | Cholesterol 20110101 |
| Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. | PloS one 20110101 |
| A cross-sectional characterization of insulin resistance by phenotype and insulin clamp in East Asian Americans with type 1 and type 2 diabetes. | PloS one 20110101 |
| PPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome. | Cardiovascular diabetology 20110101 |
| Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus. | Mediators of inflammation 20110101 |
| The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL. | PloS one 20110101 |
| Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. | PloS one 20110101 |
| PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells. | PPAR research 20110101 |
| Early peroxisome proliferator-activated receptor gamma regulated genes involved in expansion of pancreatic beta cell mass. | BMC medical genomics 20110101 |
| Alternative therapies useful in the management of diabetes: A systematic review. | Journal of pharmacy & bioallied sciences 20110101 |
| Rosiglitazone and pioglitazone alter aromatase kinetic properties in human granulosa cells. | PPAR research 20110101 |
| Preparation and characterization of pioglitazone cyclodextrin inclusion complexes. | Journal of young pharmacists : JYP 20110101 |
| Macrophages, meta-inflammation, and immuno-metabolism. | TheScientificWorldJournal 20110101 |
| The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. | Journal of advanced pharmaceutical technology & research 20110101 |
| Srebf1a is a key regulator of transcriptional control for adipogenesis. | Scientific reports 20110101 |
| Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay. | ISRN pharmaceutics 20110101 |
| Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator. | Nephron extra 20110101 |
| Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions? | Pulmonary circulation 20110101 |
| Adiponectin action: a combination of endocrine and autocrine/paracrine effects. | Frontiers in endocrinology 20110101 |
| Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids. | Frontiers in endocrinology 20110101 |
| Control of Brown Adipose Tissue Glucose and Lipid Metabolism by PPARγ. | Frontiers in endocrinology 20110101 |
| Differentiation of Human Adipose-Derived Stem Cells into 'Brite' (Brown-in-White) Adipocytes. | Frontiers in endocrinology 20110101 |
| Nisshesha rechaka pranayama offers benefits through brief intermittent hypoxia. | Ayu 20110101 |
| Thiazolidinedione therapy for managing metabolic syndrome. | American family physician 20101215 |
| Thiazolidinediones as a novel class of algicides against red tide harmful algal species. | Applied biochemistry and biotechnology 20101201 |
| Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20101201 |
| Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. | Current osteoporosis reports 20101201 |
| Smoking and risk for diabetes incidence and mortality in Korean men and women. | Diabetes care 20101201 |
| Amelioration of insulin resistance by scopoletin in high-glucose-induced, insulin-resistant HepG2 cells. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20101201 |
| The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. | Diabetes research and clinical practice 20101201 |
| Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us? | Diabetes, obesity & metabolism 20101201 |
| Synergistic effects of ascorbic acid and thiazolidinedione on secretion of high molecular weight adiponectin from human adipocytes. | Diabetes, obesity & metabolism 20101201 |
| Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus. | Korean diabetes journal 20101201 |
| The Small Rice Bowl-Based Meal Plan was Effective at Reducing Dietary Energy Intake, Body Weight, and Blood Glucose Levels in Korean Women with Type 2 Diabetes Mellitus. | Korean diabetes journal 20101201 |
| Insulin tolerance test predicts the effectiveness of insulin sensitizers in japanese type 2 diabetic patients. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201 |
| Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. | Journal of atherosclerosis and thrombosis 20101127 |
| Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-γ activators. | Bioorganic & medicinal chemistry letters 20101115 |
| Vildagliptin: a review of its use in type 2 diabetes mellitus. | Drugs 20101112 |
| New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. | Breast cancer research and treatment 20101101 |
| Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. | Diabetes research and clinical practice 20101101 |
| A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. | Diabetes care 20101101 |
| Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. | Diabetes care 20101101 |
| Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. | Current opinion in rheumatology 20101101 |
| Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition. | Toxicology and applied pharmacology 20101101 |
| Pparg-P465L mutation worsens hyperglycemia in Ins2-Akita female mice via adipose-specific insulin resistance and storage dysfunction. | Diabetes 20101101 |
| The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. | Current cardiology reports 20101101 |
| Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. | Diabetes, obesity & metabolism 20101101 |
| Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. | Diabetic medicine : a journal of the British Diabetic Association 20101101 |
| Pravastatin potentiates increases in serum adiponectin concentration in dyslipidemic patients receiving thiazolidinedione: the DOLPHIN study. | Journal of atherosclerosis and thrombosis 20101027 |
| Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. | Drugs 20101022 |
| Alogliptin: a review of its use in the management of type 2 diabetes mellitus. | Drugs 20101022 |
| Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. | Human molecular genetics 20101015 |
| Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. | European journal of clinical pharmacology 20101001 |
| Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. | Diabetes care 20101001 |
| Hidden complexities in assessment of glycemic outcomes: are quality rankings aligned with treatment? | Diabetes care 20101001 |
| Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. | Diabetes 20101001 |
| Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. | Diabetes care 20101001 |
| Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. | Diabetes care 20101001 |
| Fat tissue, aging, and cellular senescence. | Aging cell 20101001 |
| Diabetes and bone. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20101001 |
| Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. | Diabetes/metabolism research and reviews 20101001 |
| Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. | Diabetic medicine : a journal of the British Diabetic Association 20101001 |
| [Suspension of the commercialization of sibutramine and rosiglitazone in Europe]. | Revue medicale de Liege 20101001 |
| Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. | The American journal of geriatric pharmacotherapy 20101001 |
| Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. | Journal of bone and mineral metabolism 20100901 |
| Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage. | Diabetologia 20100901 |
| The small molecule phenamil is a modulator of adipocyte differentiation and PPARgamma expression. | Journal of lipid research 20100901 |
| Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. | European journal of cell biology 20100901 |
| Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass. | Diabetes 20100901 |
| Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. | Bioorganic & medicinal chemistry letters 20100901 |
| Pioglitazone in the treatment of NASH: the role of adiponectin. | Alimentary pharmacology & therapeutics 20100901 |
| Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. | Clinical pharmacokinetics 20100901 |
| Effects of in vitro insulin and 2,4-thiazolidinedione on the function of neutrophils harvested from blood of cows in different physiological states. | Journal of dairy science 20100901 |
| Aiming drug discovery at lysophosphatidic acid targets. | British journal of pharmacology 20100901 |
| Cellularity and adipogenic profile of the abdominal subcutaneous adipose tissue from obese adolescents: association with insulin resistance and hepatic steatosis. | Diabetes 20100901 |
| cis9, trans11-Conjugated Linoleic Acid Differentiates Mouse 3T3-L1 Preadipocytes into Mature Small Adipocytes through Induction of Peroxisome Proliferator-activated Receptor γ. | Journal of clinical biochemistry and nutrition 20100901 |
| Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. | The Journal of biological chemistry 20100827 |
| Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain. | Chemistry & biology 20100827 |
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. | Lancet (London, England) 20100807 |
| Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution. | Aging cell 20100801 |
| Beta-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. | Diabetes care 20100801 |
| Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. | Bioorganic & medicinal chemistry letters 20100801 |
| Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. | Diabetes, obesity & metabolism 20100801 |
| Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. | Diabetes, obesity & metabolism 20100801 |
| Simulated physician learning program improves glucose control in adults with diabetes. | Diabetes care 20100801 |
| Recommendations for management of diabetes during Ramadan: update 2010. | Diabetes care 20100801 |
| Are individuals with diabetes seeing better?: a long-term epidemiological perspective. | Diabetes 20100801 |
| Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study. | Acta cardiologica 20100801 |
| Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. | Indian journal of pharmacology 20100801 |
| Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. | JAMA 20100728 |
| Gene expression profiling of 3T3-L1 adipocytes exposed to phloretin. | The Journal of nutritional biochemistry 20100701 |
| The evolving place of incretin-based therapies in type 2 diabetes. | Pediatric nephrology (Berlin, Germany) 20100701 |
| Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. | Diabetologia 20100701 |
| Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. | Diabetologia 20100701 |
| The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. | Diabetes care 20100701 |
| Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. | Current medical research and opinion 20100701 |
| Bone loss and fracture risk associated with thiazolidinedione therapy. | Pharmacotherapy 20100701 |
| Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). | Pharmacoepidemiology and drug safety 20100701 |
| Diabetes and cancer: a consensus report. | Diabetes care 20100701 |
| GIP: an inconsequential incretin or not? | Diabetes care 20100701 |
| Dietary polyphenols and obesity. | Nutrients 20100701 |
| Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. | Cell metabolism 20100609 |
| Identification of novel metabolic pathways of pioglitazone in hepatocytes: N-glucuronidation of thiazolidinedione ring and sequential ring-opening pathway. | Drug metabolism and disposition: the biological fate of chemicals 20100601 |
| DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. | Diabetes care 20100601 |
| Self-organizing molecular field analysis of 2,4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors. | European journal of medicinal chemistry 20100601 |
| Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. | Diabetes 20100601 |
| Long-term metformin use is associated with decreased risk of breast cancer. | Diabetes care 20100601 |
| Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes. | Diabetes 20100601 |
| Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. | Diabetes care 20100601 |
| Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. | Diabetes care 20100601 |
| A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. | Current medical research and opinion 20100601 |
| Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. | Annals of the rheumatic diseases 20100601 |
| Identification of new non-carboxylic acid containing inhibitors of aldose reductase. | Bioorganic & medicinal chemistry 20100601 |
| Effects of thiazolidinediones and sulfonylureas in patients with diabetes. | Diabetes technology & therapeutics 20100601 |
| Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands. | Bioorganic & medicinal chemistry 20100601 |
| Neuropathy, retinopathy, and glucose-lowering treatments. | Diabetes care 20100601 |
| Molecular mechanism of insulin resistance in obesity and type 2 diabetes. | The Korean journal of internal medicine 20100601 |
| Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20100601 |
| Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20100501 |
| A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks. | Circulation. Cardiovascular quality and outcomes 20100501 |
| Suppressive effect of insulin infusion on chemokines and chemokine receptors. | Diabetes care 20100501 |
| Correlates of trabecular and cortical volumetric bone mineral density of the radius and tibia in older men: the Osteoporotic Fractures in Men Study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100501 |
| [Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group]. | Der Internist 20100501 |
| Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. | The Annals of pharmacotherapy 20100501 |
| Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study. | Echocardiography (Mount Kisco, N.Y.) 20100501 |
| [Difference between biguanide and thiazolidinedione, and the significance of combination therapy of biguanide and thiazolidinedione]. | Nihon rinsho. Japanese journal of clinical medicine 20100501 |
| Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. | Postgraduate medicine 20100501 |
| High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. | Journal of diabetes science and technology 20100501 |
| Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? | International journal of clinical practice 20100501 |
| Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. | Circulation 20100427 |
| Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. | Journal of the American College of Cardiology 20100427 |
| Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20100401 |
| Sulphonyurea as a cause of severe hypoglycaemia in the community. | Primary care diabetes 20100401 |
| Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. | Diabetes care 20100401 |
| Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. | European heart journal 20100401 |
| Critical role for osteopontin in diabetic nephropathy. | Kidney international 20100401 |
| Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. | Endocrinology 20100401 |
| Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20100401 |
| Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. | Diabetes, obesity & metabolism 20100401 |
| Cytotoxicity and utility of 1-indanone in the synthesis of some new heterocycles. | Chemical & pharmaceutical bulletin 20100401 |
| Synthesis and glycogen phosphorylase inhibitor activity of functionalized 1,4-benzodioxanes. | Die Pharmazie 20100401 |
| Small Rice Bowl-Based Meal Plan versus Food Exchange-Based Meal Plan for Weight, Glucose and Lipid Control in Obese Type 2 Diabetic Patients. | Korean diabetes journal 20100401 |
| Thiazolidinedione precipitated thyroid associated ophthalmopathy. | The Journal of the Association of Physicians of India 20100401 |
| Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. | Journal of medicinal chemistry 20100325 |
| The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. | American journal of epidemiology 20100315 |
| The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. | Molecular carcinogenesis 20100301 |
| Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. | Diabetes care 20100301 |
| Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. | Diabetes 20100301 |
| Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. | Journal of thrombosis and haemostasis : JTH 20100301 |
| Synthesis and electrochemical studies of charge-transfer complexes of thiazolidine-2,4-dione with sigma and pi acceptors. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20100301 |
| Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents. | Bioorganic & medicinal chemistry 20100301 |
| Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. | Pharmacotherapy 20100301 |
| Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. | Archives of ophthalmology (Chicago, Ill. : 1960) 20100301 |
| Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. | Neoplasia (New York, N.Y.) 20100301 |
| Potential health-modulating effects of isoflavones and metabolites via activation of PPAR and AhR. | Nutrients 20100301 |
| Binding of histidine in the (Cys)3(His)1-coordinated [2Fe-2S] cluster of human mitoNEET. | Journal of the American Chemical Society 20100217 |
| In vivo effects of rosiglitazone in a human neuroblastoma xenograft. | British journal of cancer 20100216 |
| Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors. | Bioorganic & medicinal chemistry 20100215 |
| Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100201 |
| Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. | Toxicology letters 20100201 |
| Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. | Diabetes care 20100201 |
| Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. | Diabetes, obesity & metabolism 20100201 |
| Thiazolidinediones induce Rab7-RILP-MAPK-dependent juxtanuclear lysosome aggregation and reduce tumor cell invasion. | Traffic (Copenhagen, Denmark) 20100201 |
| Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. | The Journal of clinical endocrinology and metabolism 20100201 |
| Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists. | Bioorganic & medicinal chemistry letters 20100201 |
| Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET. | Bioorganic & medicinal chemistry letters 20100201 |
| Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? | Hepatology (Baltimore, Md.) 20100201 |
| [Recent advances in PPARgamma research]. | Nihon rinsho. Japanese journal of clinical medicine 20100201 |
| [PPARgamma target genes and the molecular mechanism of transcriptional control by PPARgamma]. | Nihon rinsho. Japanese journal of clinical medicine 20100201 |
| [Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma]. | Nihon rinsho. Japanese journal of clinical medicine 20100201 |
| [PPARgamma agonists for the diseases of gastrointestinal tract and liver]. | Nihon rinsho. Japanese journal of clinical medicine 20100201 |
| [PPARgamma antagonist as a potential drug for the treatment of obesity and diabetes]. | Nihon rinsho. Japanese journal of clinical medicine 20100201 |
| Thiazolidinedione attenuate proteinuria and glomerulosclerosis in Adriamycin-induced nephropathy rats via slit diaphragm protection. | Nephrology (Carlton, Vic.) 20100201 |
| Role of PPARs in Radiation-Induced Brain Injury. | PPAR research 20100101 |
| Many Americans have pre-diabetes and should be considered for metformin therapy. | Diabetes care 20100101 |
| Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. | Diabetes care 20100101 |
| Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2. | PPAR research 20100101 |
| The effects of rosiglitazone and high glucose on protein expression in endothelial cells. | Journal of proteome research 20100101 |
| Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. | ASN neuro 20100101 |
| Troglitazone. | Handbook of experimental pharmacology 20100101 |
| PPARs in Irradiation-Induced Gastrointestinal Toxicity. | PPAR research 20100101 |
| Aspects of insulin treatment. | Diabetes care 20100101 |
| Standards of medical care in diabetes--2010. | Diabetes care 20100101 |
| Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection. | BMC infectious diseases 20100101 |
| Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. | Postgraduate medicine 20100101 |
| Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. | Cardiovascular diabetology 20100101 |
| The thiazolidinedione pioglitazone increases cholesterol biosynthetic gene expression in primary cortical neurons by a PPARgamma-independent mechanism. | Journal of Alzheimer's disease : JAD 20100101 |
| Biguanide, but not thiazolidinedione, improved insulin resistance in Werner syndrome. | Journal of the American Geriatrics Society 20100101 |
| Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies. | Reproductive biology and endocrinology : RB&E 20100101 |
| Ambient air pollution and the progression of atherosclerosis in adults. | PloS one 20100101 |
| Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction. | Journal of biomedicine & biotechnology 20100101 |
| Genetic variation in the adiponectin receptor 2 (ADIPOR2) gene is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes. | Cardiovascular diabetology 20100101 |
| Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. | Respiratory research 20100101 |
| Therapeutic Implications of PPARgamma in Human Osteosarcoma. | PPAR research 20100101 |
| Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. | PPAR research 20100101 |
| Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells. | Journal of experimental & clinical cancer research : CR 20100101 |
| The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. | BMC cancer 20100101 |
| EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage. | BMC clinical pharmacology 20100101 |
| Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. | BMJ (Clinical research ed.) 20100101 |
| Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. | Patient preference and adherence 20100101 |
| Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. | Diabetes & vascular disease research 20100101 |
| Reporting bias in medical research - a narrative review. | Trials 20100101 |
| 3D-QSAR studies on a series of 5-arylidine-2, 4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach. | Medicinal chemistry (Shariqah (United Arab Emirates)) 20100101 |
| Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. | Vascular health and risk management 20100101 |
| Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. | BMC endocrine disorders 20100101 |
| PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. | Nuclear receptor signaling 20100101 |
| Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. | PloS one 20100101 |
| Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. | Vascular health and risk management 20100101 |
| Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents. | Journal of oncology 20100101 |
| Vaticanol C, a resveratrol tetramer, activates PPARalpha and PPARbeta/delta in vitro and in vivo. | Nutrition & metabolism 20100101 |
| The peroxisome proliferator-activated receptor gamma system regulates ultraviolet B-induced prostaglandin e(2) production in human epidermal keratinocytes. | PPAR research 20100101 |
| Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. | Mediators of inflammation 20100101 |
| Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. | Mediators of inflammation 20100101 |
| Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. | Therapeutics and clinical risk management 20100101 |
| Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. | PloS one 20100101 |
| The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. | BMC gastroenterology 20100101 |
| Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. | Cardiology in review 20100101 |
| Notch and Wnt signaling, physiological stimuli and postnatal myogenesis. | International journal of biological sciences 20100101 |
| Exenatide: a new promising antidiabetic agent. | Indian journal of pharmaceutical sciences 20100101 |
| Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects. | PPAR research 20100101 |
| Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. | PPAR research 20100101 |
| Various Terpenoids Derived from Herbal and Dietary Plants Function as PPAR Modulators and Regulate Carbohydrate and Lipid Metabolism. | PPAR research 20100101 |
| Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. | BMC cancer 20100101 |
| Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats. | PPAR research 20100101 |
| The tsim tsoum approaches for prevention of cardiovascular disease. | Cardiology research and practice 20100101 |
| Women have higher protein content of beta-oxidation enzymes in skeletal muscle than men. | PloS one 20100101 |
| Peroxisome proliferator-activated receptors alpha, Beta, and gamma mRNA and protein expression in human fetal tissues. | PPAR research 20100101 |
| Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. | Health and quality of life outcomes 20100101 |
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | Frontiers in aging neuroscience 20100101 |
| Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. | Vascular health and risk management 20100101 |
| Effect of pioglitazone on platelet aggregation in a healthy cohort. | Cardiology 20100101 |
| Biliary innate immunity: function and modulation. | Mediators of inflammation 20100101 |
| Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. | Cardiovascular diabetology 20100101 |
| Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob/ob mice. | PloS one 20100101 |
| Coactivators in PPAR-Regulated Gene Expression. | PPAR research 20100101 |
| AMPK-Dependent Metabolic Regulation by PPAR Agonists. | PPAR research 20100101 |
| Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. | BMC gastroenterology 20100101 |
| Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. | BMC surgery 20100101 |
| Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells. | Neuroendocrinology 20100101 |
| Validated high performance thin layer chromatographic determination and content uniformity test for rosiglitazone in tablets. | Indian journal of pharmaceutical sciences 20100101 |
| Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. | Cardiovascular diabetology 20100101 |
| Peroxisome proliferator-activated receptors (PPARs)-independent functions of fish oil on glucose and lipid metabolism in diet-induced obese mice. | Lipids in health and disease 20100101 |
| Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. | Therapeutics and clinical risk management 20100101 |
| [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]. | Revue medicale de Liege 20100101 |
| Beta-arrestin inhibits CAMKKbeta-dependent AMPK activation downstream of protease-activated-receptor-2. | BMC biochemistry 20100101 |
| Exenatide once weekly: clinical outcomes and patient satisfaction. | Patient preference and adherence 20100101 |
| Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. | Vascular health and risk management 20100101 |
| The thiazolidinedione controversy in cardiovascular risk. | Preventive cardiology 20100101 |
| Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation. | PPAR research 20100101 |
| Peroxisome Proliferator-Activated Receptors Protect against Apoptosis via 14-3-3. | PPAR research 20100101 |
| Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. | Cardiovascular diabetology 20100101 |
| PPARs in Rhythmic Metabolic Regulation and Implications in Health and Disease. | PPAR research 20100101 |
| Stability-indicating validated HPLC method for simultaneous determination of oral antidiabetic drugs from thiazolidinedione and sulfonylurea groups in combined dosage forms. | Journal of AOAC International 20100101 |
| The role of PPARγ for the osteoblastic differentiation. | Journal of endocrinological investigation 20100101 |
| Coordinate Transcriptomic and Metabolomic Effects of the Insulin Sensitizer Rosiglitazone on Fundamental Metabolic Pathways in Liver, Soleus Muscle, and Adipose Tissue in Diabetic db/db Mice. | PPAR research 20100101 |
| Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism. | PPAR research 20100101 |
| Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. | PPAR research 20100101 |
| Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. | Core evidence 20100101 |
| Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. | Diabetology & metabolic syndrome 20100101 |
| High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships. | PloS one 20100101 |
| Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands. | BMC cancer 20100101 |
| Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. | PloS one 20100101 |
| Peroxisome Proliferator-Activated Receptor -β/δ, -γ Agonists and Resveratrol Modulate Hypoxia Induced Changes in Nuclear Receptor Activators of Muscle Oxidative Metabolism. | PPAR research 20100101 |
| Liraglutide in the management of type 2 diabetes. | Drug design, development and therapy 20100101 |
| Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. | BMC endocrine disorders 20100101 |
| Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. | Journal of molecular signaling 20100101 |
| Gestational diabetes: risks, management, and treatment options. | International journal of women's health 20100101 |
| Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. | Clinical interventions in aging 20100101 |
| The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session. | Diabetology & metabolic syndrome 20100101 |
| Treatment of dyslipidemia in patients with type 2 diabetes. | Lipids in health and disease 20100101 |
| Metabolic syndrome and cardiovascular risk. | Journal of family & community medicine 20100101 |
| Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Emerging role of GLP-1 receptor agonists in the treatment of obesity. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Saxagliptin for type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Adipocytokines: The pied pipers. | Journal of pharmacology & pharmacotherapeutics 20100101 |
| Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease. | Journal of inflammation research 20100101 |
| New and emerging agents in the management of lipodystrophy in HIV-infected patients. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Managing insulin resistance: role of liraglutide. | Clinical pharmacology : advances and applications 20100101 |
| Pharmacological management of metabolic syndrome and its lipid complications. | Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20100101 |
| Case series of liver failure associated with rosiglitazone and pioglitazone. | Pharmacoepidemiology and drug safety 20091201 |
| Synergistic effect of phytochemicals in combination with hypoglycemic drugs on glucose uptake in myotubes. | Phytomedicine : international journal of phytotherapy and phytopharmacology 20091201 |
| Change of initial oral antidiabetic therapy in type 2 diabetic patients. | Pharmacy world & science : PWS 20091201 |
| CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. | Fundamental & clinical pharmacology 20091201 |
| Diabetes and fractures: an overshadowed association. | Current opinion in endocrinology, diabetes, and obesity 20091201 |
| Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. | The Journal of clinical endocrinology and metabolism 20091201 |
| Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. | Diabetes, obesity & metabolism 20091201 |
| Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. | Diabetes, obesity & metabolism 20091201 |
| Ppargamma2 is a key driver of longevity in the mouse. | PLoS genetics 20091201 |
| Pharmacologic management of the older patient with type 2 diabetes mellitus. | The American journal of geriatric pharmacotherapy 20091201 |
| Diabetes and skeletal health. | Journal of diabetes 20091201 |
| Augmentation of PPARgamma-TAZ interaction contributes to the anti-adipogenic activity of KR62980. | Biochemical pharmacology 20091115 |
| Redox characterization of the FeS protein MitoNEET and impact of thiazolidinedione drug binding. | Biochemistry 20091103 |
| Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. | Diabetes 20091101 |
| Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. | Diabetes 20091101 |
| Evidence of anti-inflammatory effects of pioglitazone in the murine pleurisy model induced by carrageenan. | International immunopharmacology 20091101 |
| The origin of intermuscular adipose tissue and its pathophysiological implications. | American journal of physiology. Endocrinology and metabolism 20091101 |
| Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects. | Bioorganic & medicinal chemistry letters 20091101 |
| Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. | Diabetes care 20091101 |
| Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy. | Diabetes care 20091101 |
| Changing the treatment paradigm for type 2 diabetes. | Diabetes care 20091101 |
| Incretin-based therapies: viewpoints on the way to consensus. | Diabetes care 20091101 |
| Early insulin treatment in type 2 diabetes: what are the pros? | Diabetes care 20091101 |
| Metabolomics applied to diabetes research: moving from information to knowledge. | Diabetes 20091101 |
| [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2]. | Medizinische Monatsschrift fur Pharmazeuten 20091101 |
| Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. | Chemico-biological interactions 20091030 |
| Saxagliptin. | Drugs 20091022 |
| Treatment of hypertension in children and adolescents. | Pediatric nephrology (Berlin, Germany) 20091001 |
| No association of multiple type 2 diabetes loci with type 1 diabetes. | Diabetologia 20091001 |
| Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. | Diabetes care 20091001 |
| Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study. | Diabetes, obesity & metabolism 20091001 |
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | Current medical research and opinion 20091001 |
| Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. | Hepatology (Baltimore, Md.) 20091001 |
| Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. | Behavioural pharmacology 20091001 |
| Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. | European journal of medicinal chemistry 20090901 |
| Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. | Diabetes care 20090901 |
| Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists. | Anti-cancer agents in medicinal chemistry 20090901 |
| Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. | American journal of physiology. Endocrinology and metabolism 20090901 |
| Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. | International journal of clinical practice 20090901 |
| Emerging drugs for conjunctivitis. | Expert opinion on emerging drugs 20090901 |
| Slower decline of renal function after initiation of rosiglitazone in diabetics -- a pilot study. | Clinical nephrology 20090901 |
| A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial. | Diabetes technology & therapeutics 20090901 |
| The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. | PLoS medicine 20090901 |
| Proteomic characterization of thiazolidinedione regulation of obese adipose secretome in Zucker obese rats. | Proteomics. Clinical applications 20090901 |
| Adiponectin and thiazolidinedione targets CRTC2 to regulate hepatic gluconeogenesis. | Experimental & molecular medicine 20090831 |
| Thiazolidinediones and fractures in men and women. | Archives of internal medicine 20090810 |
| Synthesis and in vivo antidiabetic activity of novel dispiropyrrolidines through [3+2] cycloaddition reactions with thiazolidinedione and rhodanine derivatives. | European journal of medicinal chemistry 20090801 |
| Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents. | Pharmacoepidemiology and drug safety 20090801 |
| Gsalpha signalling suppresses PPARgamma2 generation and inhibits 3T3L1 adipogenesis. | The Journal of endocrinology 20090801 |
| The role of pioglitazone in modifying the atherogenic lipoprotein profile. | Diabetes, obesity & metabolism 20090801 |
| Effects of prepartum 2,4-thiazolidinedione on metabolism and performance in transition dairy cows. | Journal of dairy science 20090801 |
| Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. | Journal of Korean medical science 20090801 |
| Distal upper and lower limb fractures associated with thiazolidinedione use. | The American journal of managed care 20090801 |
| Thiazolidinediones and cardiovascular risk - a question of balance. | Current cardiology reviews 20090801 |
| [Inhibitory effects of thiazolidinedione upon cytokine-induced apoptosis in pancreatic beta-cell line]. | Zhonghua yi xue za zhi 20090728 |
| CoMFA and CoMSIA analysis of 2,4-thiazolidinediones derivatives as aldose reductase inhibitors. | Journal of molecular modeling 20090701 |
| Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090701 |
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Diabetes care 20090701 |
| Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? | Journal of clinical gastroenterology 20090701 |
| Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs. | British journal of pharmacology 20090701 |
| Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. | Diabetes 20090701 |
| Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. | Diabetes care 20090701 |
| Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein. | Molecular pharmacology 20090701 |
| Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion. | American journal of physiology. Gastrointestinal and liver physiology 20090701 |
| Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. | Current medical research and opinion 20090701 |
| Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes. | The Journal of antibiotics 20090701 |
| Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. | Pharmacotherapy 20090701 |
| Drug titration patterns and HbA 1c levels in type 2 diabetes. | International journal of clinical practice 20090701 |
| The novel 2Fe-2S outer mitochondrial protein mitoNEET displays conformational flexibility in its N-terminal cytoplasmic tethering domain. | Acta crystallographica. Section F, Structural biology and crystallization communications 20090701 |
| Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). | The American journal of cardiology 20090701 |
| The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. | The Journal of biological chemistry 20090626 |
| Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090623 |
| A randomized trial of therapies for type 2 diabetes and coronary artery disease. | The New England journal of medicine 20090611 |
| [Thiazolidinediones and skeletal health]. | Revue medicale suisse 20090610 |
| Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). | Journal of the American College of Cardiology 20090602 |
| Fixed-dose single tablet antidiabetic combinations. | Diabetes, obesity & metabolism 20090601 |
| Role of hydrogen bonding on the spectroscopic properties of thiazolidinedione derivatives in homogeneous solvents. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20090601 |
| Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20090601 |
| Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). | Diabetes care 20090601 |
| Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. | Pharmacoepidemiology and drug safety 20090601 |
| Abdominal subcutaneous adipose tissue: a protective fat depot? | Diabetes care 20090601 |
| FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. | Diabetes 20090601 |
| DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. | Diabetes care 20090601 |
| The lipin family: mutations and metabolism. | Current opinion in lipidology 20090601 |
| Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090515 |
| Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. | Obesity (Silver Spring, Md.) 20090501 |
| Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. | Kidney international 20090501 |
| One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. | Diabetes care 20090501 |
| Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. | Hepatology (Baltimore, Md.) 20090501 |
| PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients. | Diabetes care 20090501 |
| n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. | Diabetologia 20090501 |
| Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials. | Bioorganic & medicinal chemistry letters 20090501 |
| Rosiglitazone is associated with mortality in chronic hemodialysis patients. | Journal of the American Society of Nephrology : JASN 20090501 |
| Translating science into clinical practice: focus on vildagliptin in combination with metformin. | Diabetes, obesity & metabolism 20090501 |
| Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. | Diabetes 20090501 |
| Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. | Advances in therapy 20090501 |
| Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. | International journal of clinical pharmacology and therapeutics 20090501 |
| Cardiovascular risk and TZD: safe therapy for the elderly? | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20090501 |
| High-throughput quantification of a novel thiazolidinedione MCC-555 in rat plasma by ultra-fast liquid chromatography and its application in pharmacokinetic studies. | Talanta 20090430 |
| PPARgamma-independent antitumor effects of thiazolidinediones. | Cancer letters 20090418 |
| S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats. | European journal of pharmacology 20090417 |
| Thiazolidinedione use and the risk of fractures. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090414 |
| Thiazolidinedione use and the risk of fractures. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090414 |
| Antidiabetic action of bezafibrate in a large observational database. | Diabetes care 20090401 |
| Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis. | Diabetes 20090401 |
| Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. | Journal of the American Society of Nephrology : JASN 20090401 |
| Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. | Arteriosclerosis, thrombosis, and vascular biology 20090401 |
| Rosiglitazone acts as a neuroprotectant in retinal cells via up-regulation of sestrin-1 and SOD-2. | Journal of neurochemistry 20090401 |
| Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives. | Chemical biology & drug design 20090401 |
| AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. | Clinical science (London, England : 1979) 20090401 |
| Pharmacogenetics in diabetes. | Current diabetes reports 20090401 |
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. | Diabetes 20090401 |
| INT131: a selective modulator of PPAR gamma. | Journal of molecular biology 20090313 |
| Dact1, a nutritionally regulated preadipocyte gene, controls adipogenesis by coordinating the Wnt/beta-catenin signaling network. | Diabetes 20090301 |
| Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. | Diabetes 20090301 |
| Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. | Current medical research and opinion 20090301 |
| Subchronic toxicity and toxicokinetics of MCC-555, a novel thiazolidinedione, after 270-day repeated oral administration in dogs. | Environmental toxicology and pharmacology 20090301 |
| Preserved glucose tolerance in high-fat-fed C57BL/6 mice transplanted with PPARgamma-/-, PPARdelta-/-, PPARgammadelta-/-, or LXRalphabeta-/- bone marrow. | Journal of lipid research 20090201 |
| Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice. | Endocrinology 20090201 |
| Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats. | The Journal of endocrinology 20090201 |
| Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. | Diabetes care 20090201 |
| Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. | Clinica chimica acta; international journal of clinical chemistry 20090201 |
| BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. | American journal of physiology. Cell physiology 20090201 |
| PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. | Journal of cellular biochemistry 20090201 |
| Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. | International journal of obesity (2005) 20090201 |
| Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. | Bioorganic & medicinal chemistry 20090115 |
| The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. | European journal of pharmacology 20090114 |
| Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. | Journal of medicinal chemistry 20090108 |
| Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20090106 |
| Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). | Atherosclerosis 20090101 |
| Hydroxyl and superoxide radical scavenging abilities of chromonyl-thiazolidine-2,4-dione compounds. | Luminescence : the journal of biological and chemical luminescence 20090101 |
| Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. | Contemporary clinical trials 20090101 |
| Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. | Diabetes care 20090101 |
| Substituent effect on the emission behavior of thiazolidinedione derivatives in cationic and anionic micellar media. | Journal of colloid and interface science 20090101 |
| Flow cytometry-based binding assay for GPR40 (FFAR1; free fatty acid receptor 1). | Molecular pharmacology 20090101 |
| Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. | Diabetologia 20090101 |
| Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. | Clinical journal of the American Society of Nephrology : CJASN 20090101 |
| HIV-1 infection and the PPARγ-dependent control of adipose tissue physiology. | PPAR research 20090101 |
| The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. | PPAR research 20090101 |
| Summary of revisions for the 2009 Clinical Practice Recommendations. | Diabetes care 20090101 |
| Executive summary: standards of medical care in diabetes--2009. | Diabetes care 20090101 |
| Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy. | Journal of biomedicine & biotechnology 20090101 |
| Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. | BMC research notes 20090101 |
| [Heart failure with thiazolidinedione treatment: what do we know today?]. | Deutsche medizinische Wochenschrift (1946) 20090101 |
| The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale. | Diabetes & vascular disease research 20090101 |
| Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment. | Cardiovascular diabetology 20090101 |
| Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. | Endocrine journal 20090101 |
| Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. | BMC health services research 20090101 |
| Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. | Trials 20090101 |
| Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. | Clinical therapeutics 20090101 |
| Scavenging capacities of some thiazolyl thiazolidine-2,4-dione compounds on superoxide radical, hydroxyl radical, and DPPH radical. | Luminescence : the journal of biological and chemical luminescence 20090101 |
| [Prevalence of arterial hypertension in women with type 2 diabetes mellitus and diabetic foot syndrome]. | Klinicheskaia meditsina 20090101 |
| Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice. | European journal of medical research 20090101 |
| Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. | Molecular cancer 20090101 |
| The mixed-lineage kinase DLK is a key regulator of 3T3-L1 adipocyte differentiation. | PloS one 20090101 |
| Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. | BMC systems biology 20090101 |
| Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. | Cardiovascular diabetology 20090101 |
| Is PPARγ a prospective player in HIV-1-associated bone disease? | PPAR research 20090101 |
| PPARδ activity in cardiovascular diseases: A potential pharmacological target. | PPAR research 20090101 |
| Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. | BMC endocrine disorders 20090101 |
| Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study. | Drug safety 20090101 |
| PPARγ2 polymorphism and human health. | PPAR research 20090101 |
| PPAR and liver injury in HIV-infected patients. | PPAR research 20090101 |
| Postprandial hyperglycemia as an etiological factor in vascular failure. | Cardiovascular diabetology 20090101 |
| MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation. | PPAR research 20090101 |
| Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. | BMC research notes 20090101 |
| Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. | Cost effectiveness and resource allocation : C/E 20090101 |
| Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. | Cardiovascular therapeutics 20090101 |
| Alterations in transcriptional responses associated with vascular aging. | Journal of inflammation (London, England) 20090101 |
| Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. | BMC cancer 20090101 |
| Safety and efficacy of rosiglitazone in the elderly diabetic patient. | Vascular health and risk management 20090101 |
| Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. | Nutrition journal 20090101 |
| Treatment of postherpetic neuralgia: focus on pregabalin. | Clinical interventions in aging 20090101 |
| Factors associated with results and conclusions of trials of thiazolidinediones. | PloS one 20090101 |
| Activation of PPARγ by Rosiglitazone does not negatively impact male sex steroid hormones in diabetic rats. | PPAR research 20090101 |
| Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats. | PPAR research 20090101 |
| Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. | Lipids in health and disease 20090101 |
| Management of progressive type 2 diabetes: role of insulin therapy. | Osteopathic medicine and primary care 20090101 |
| New target genes for the peroxisome proliferator-activated receptor-γ (PPARγ) antitumour activity: Perspectives from the insulin receptor. | PPAR research 20090101 |
| Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. | Cardiovascular diabetology 20090101 |
| PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. | PPAR research 20090101 |
| Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. | Experimental diabetes research 20090101 |
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | Cardiovascular diabetology 20090101 |
| The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. | Cardiovascular diabetology 20090101 |
| PPARs in Viral Disease. | PPAR research 20090101 |
| Actos Now for the prevention of diabetes (ACT NOW) study. | BMC endocrine disorders 20090101 |
| Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. | Cardiovascular diabetology 20090101 |
| PPAR research: Successful launching and promising future. | PPAR research 20090101 |
| Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. | PPAR research 20090101 |
| Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program. | PloS one 20090101 |
| Common polymorphisms within the NR4A3 locus, encoding the orphan nuclear receptor Nor-1, are associated with enhanced beta-cell function in non-diabetic subjects. | BMC medical genetics 20090101 |
| Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. | BMJ (Clinical research ed.) 20090101 |
| Effect of food restriction on adipose tissue in spontaneously diabetic Torii fatty rats. | Experimental diabetes research 20090101 |
| Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? | PPAR research 20090101 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. | Endocrine journal 20090101 |
| Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. | Therapeutics and clinical risk management 20090101 |
| Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. | Cardiovascular diabetology 20090101 |
| Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice. | Pharmacology 20090101 |
| Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta. | PloS one 20090101 |
| Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas. | Journal of oncology 20090101 |
| Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. | BMC nephrology 20090101 |
| Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. | Health and quality of life outcomes 20090101 |
| Current understanding of the role of PPARγ in gastrointestinal cancers. | PPAR research 20090101 |
| Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells. | PloS one 20090101 |
| A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. | PloS one 20090101 |
| Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. | Vascular health and risk management 20090101 |
| A review of exenatide as adjunctive therapy in patients with type 2 diabetes. | Drug design, development and therapy 20090101 |
| Inverse association between insulin resistance and gait speed in nondiabetic older men: results from the U.S. National Health and Nutrition Examination Survey (NHANES) 1999-2002. | BMC geriatrics 20090101 |
| Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts. | Molecular vision 20090101 |
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | BMJ (Clinical research ed.) 20090101 |
| Initiation of the expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in the rat ovary and the role of FSH. | Reproductive biology and endocrinology : RB&E 20090101 |
| Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. | Reproductive biology and endocrinology : RB&E 20090101 |
| VEGF gene expression in adult human thymus fat: a correlative study with hypoxic induced factor and cyclooxygenase-2. | PloS one 20090101 |
| Differential effects of thiazolidinediones on adipocyte growth and recruitment in Zucker fatty rats. | PloS one 20090101 |
| Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. | Journal of diabetes science and technology 20090101 |
| Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin. | International journal of clinical practice 20090101 |
| Synthesis and antimicrobial activity of some novel thiazolidine-2,4-dione derivatives. | Arzneimittel-Forschung 20090101 |
| A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. | International journal of diabetes in developing countries 20090101 |
| Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPARgamma and Identification of TUSC5 Coding Variants in Lean and Obese Humans. | PPAR research 20090101 |
| Image processing techniques for assessing contractility in isolated adult cardiac myocytes. | International journal of biomedical imaging 20090101 |
| A Dominant-Negative PPARgamma Mutant Promotes Cell Cycle Progression and Cell Growth in Vascular Smooth Muscle Cells. | PPAR research 20090101 |
| Medical treatment of Cushing's disease: Overview and recent findings. | International journal of general medicine 20090101 |
| Gliptins: a new class of oral antidiabetic agents. | Indian journal of pharmaceutical sciences 20090101 |
| Resolving issues of content uniformity and low permeability using eutectic blend of camphor and menthol. | Indian journal of pharmaceutical sciences 20090101 |
| Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Analog insulin detemir for patients with type 1 and type 2 diabetes: a review. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Risk management in the treatment of type 2 diabetes with pioglitazone. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Alogliptin: a new addition to the class of DPP-4 inhibitors. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
| Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes. | Yonsei medical journal 20081231 |
| PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. | British journal of cancer 20081209 |
| Ligand-dependent and -independent regulation of PPAR gamma and orphan nuclear receptors. | Science signaling 20081202 |
| Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. | Breast cancer research and treatment 20081201 |
| [Insulin resistance and chronic kidney disease]. | Nephrologie & therapeutique 20081201 |
| Design and synthesis of 3-pyrrol-3-yl-3H-isobenzofuran-1-ones as inhibitors of human cytosolic phospholipase A2alpha. | Journal of enzyme inhibition and medicinal chemistry 20081201 |
| A double-headed cathepsin B inhibitor devoid of warhead. | Protein science : a publication of the Protein Society 20081201 |
| Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. | Gastroenterology 20081201 |
| Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. | American heart journal 20081201 |
| Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety. | Diabetes, obesity & metabolism 20081201 |
| Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. | Expert opinion on emerging drugs 20081201 |
| Thiazolidinedione associated volume overload and pulmonary hypertension. | Therapeutic advances in cardiovascular disease 20081201 |
| Bioequivalence and comparison of pharmacokinetic properties of 4-mg tablet formulations of rosiglitazone hydrochloride and rosiglitazone maleate: a single-dose, randomized, open-label, two-period crossover study in healthy adult male Chinese volunteers. | Clinical therapeutics 20081201 |
| Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. | Vascular health and risk management 20081201 |
| Vildagliptin: a new oral treatment for type 2 diabetes mellitus. | Vascular health and risk management 20081201 |
| The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. | Biologics : targets & therapy 20081201 |
| Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population. | Journal of clinical lipidology 20081201 |
| In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse pdx-1 promoter. | The Journal of biological chemistry 20081121 |
| Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones. | European journal of medicinal chemistry 20081101 |
| Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. | Diabetes care 20081101 |
| Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. | Current medical research and opinion 20081101 |
| Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. | Current medical research and opinion 20081101 |
| Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. | The Annals of pharmacotherapy 20081101 |
| The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin. | Current cardiology reviews 20081101 |
| Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. | European journal of pharmacology 20081031 |
| Expression of NAD+ dependent 15-hydroxyprostaglandin dehydrogenase and protection of prostaglandins in human hair follicle. | Experimental dermatology 20081001 |
| Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. | Archives of toxicology 20081001 |
| Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. | Diabetes 20081001 |
| Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. | American journal of physiology. Endocrinology and metabolism 20081001 |
| Weight change in diabetes and glycemic and blood pressure control. | Diabetes care 20081001 |
| Rosiglitazone and cardiovascular risk. | Current atherosclerosis reports 20081001 |
| An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. | Pharmacoepidemiology and drug safety 20081001 |
| Electrochemical oxidation of troglitazone: identification and characterization of the major reactive metabolite in liver microsomes. | Chemical research in toxicology 20081001 |
| American College Of Endocrinology Pre-Diabetes Consensus Conference: part one. | Diabetes care 20081001 |
| Troglitazone increases IL-1beta induced cyclooxygenase-2 and inducible nitric oxide synthase expression via enhanced phosphorylation of IkappaBalpha in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. | Biological & pharmaceutical bulletin 20081001 |
| Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. | Vascular health and risk management 20081001 |
| Immune system and inflammation. | Indian journal of pharmacology 20081001 |
| A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. | The Journal of biological chemistry 20080926 |
| Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. | Toxicology 20080904 |
| Importance of the high-molecular-mass isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. | Clinical science (London, England : 1979) 20080901 |
| Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. | Diabetes 20080901 |
| Pyruvate dehydrogenase kinase 4: regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue. | Diabetes 20080901 |
| Mesodermal fate decisions of a stem cell: the Wnt switch. | Cellular and molecular life sciences : CMLS 20080901 |
| The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. | International journal of cancer 20080901 |
| The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. | Diabetes 20080901 |
| Metabolically favorable remodeling of human adipose tissue by human adenovirus type 36. | Diabetes 20080901 |
| Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. | Bioorganic & medicinal chemistry 20080901 |
| Glycemic control in diabetes: a tale of three studies. | Diabetes care 20080901 |
| Circulating free fatty acids are increased independently of PPARgamma activity after administration of poloxamer 407 to mice. | Canadian journal of physiology and pharmacology 20080901 |
| Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways. | Molecular cancer therapeutics 20080901 |
| Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. | Archives of pharmacal research 20080901 |
| It's not how fat you are, it's what you do with it that counts. | PLoS biology 20080901 |
| The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway. | Yonsei medical journal 20080830 |
| Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. | Journal of medicinal chemistry 20080828 |
| Fracture risk in type 2 diabetes: update of a population-based study. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080801 |
| The novel adipocytokine visfatin exerts direct cardioprotective effects. | Journal of cellular and molecular medicine 20080801 |
| Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism. | Diabetes 20080801 |
| PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. | Diabetes 20080801 |
| Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. | Diabetes 20080801 |
| Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. | Diabetes care 20080801 |
| Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. | European journal of cancer (Oxford, England : 1990) 20080801 |
| Fatty liver and chronic inflammation in Chinese adults. | Diabetes research and clinical practice 20080801 |
| Approaches to treatment of type 2 diabetes. | Diabetes care 20080801 |
| Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. | Vascular health and risk management 20080801 |
| A high activity index of stearoyl-CoA desaturase is associated with increased risk of fracture in men. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080701 |
| Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. | Clinical endocrinology 20080701 |
| Effect of supervised progressive resistance-exercise training protocol on insulin sensitivity, glycemia, lipids, and body composition in Asian Indians with type 2 diabetes. | Diabetes care 20080701 |
| Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. | Metabolism: clinical and experimental 20080701 |
| Beyond the classic angiotensin-receptor-blocker profile. | Nature clinical practice. Cardiovascular medicine 20080701 |
| A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells. | Molecular cancer therapeutics 20080701 |
| Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand. | Naunyn-Schmiedeberg's archives of pharmacology 20080601 |
| The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. | Molecular endocrinology (Baltimore, Md.) 20080601 |
| Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008. | Cardiovascular drugs and therapy 20080601 |
| Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. | Fundamental & clinical pharmacology 20080601 |
| Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. | Diabetes, obesity & metabolism 20080601 |
| Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. | Diabetes, obesity & metabolism 20080601 |
| Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. | Bioorganic & medicinal chemistry 20080601 |
| Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure. | Expert review of cardiovascular therapy 20080601 |
| Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. | Translational research : the journal of laboratory and clinical medicine 20080601 |
| Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. | PLoS genetics 20080601 |
| Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. | Vascular health and risk management 20080601 |
| Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. | Vascular health and risk management 20080601 |
| Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. | Core evidence 20080601 |
| Troglitazone up-regulates vascular endothelial argininosuccinate synthase. | Biochemical and biophysical research communications 20080530 |
| Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal. | Nature clinical practice. Endocrinology & metabolism 20080501 |
| Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma. | The Annals of pharmacotherapy 20080501 |
| Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. | Journal of molecular and cellular cardiology 20080501 |
| [Relationship between lipid and glucose metabolism and bone mineral metabolism : pleiotropic effects of therapeutic agents for diabetes and hyperlipidemia]. | Clinical calcium 20080501 |
| Managed care perspective on three new agents for type 2 diabetes. | Journal of managed care pharmacy : JMCP 20080501 |
| Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. | Clinical therapeutics 20080501 |
| Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. | Current clinical pharmacology 20080501 |
| Use of thiazolidinediones and fracture risk. | Archives of internal medicine 20080428 |
| Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. | International journal of cardiology 20080425 |
| A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. | European journal of pharmacology 20080414 |
| T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. | The Journal of biological chemistry 20080404 |
| The influence of thiazolidinediones on adipogenesis in vitro and in vivo: potential modifiers of intramuscular adipose tissue deposition in meat animals. | Journal of animal science 20080401 |
| Assessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone. | Environmental and molecular mutagenesis 20080401 |
| Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. | Diabetologia 20080401 |
| High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naïve type 2 diabetic subjects. | Journal of internal medicine 20080401 |
| Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients. | Metabolism: clinical and experimental 20080401 |
| Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? | Diabetes, obesity & metabolism 20080401 |
| Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats. | Xenobiotica; the fate of foreign compounds in biological systems 20080401 |
| PROactive: time for a critical appraisal. | European heart journal 20080401 |
| Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. | Vascular health and risk management 20080401 |
| Formulation and hypoglycemic activity of pioglitazone-cyclodextrin inclusion complexes. | Drug discoveries & therapeutics 20080401 |
| Electrophilic alpha-thiocyanation of chiral and achiral N-acyl imides. A convenient route to 5-substituted and 5,5-disubstituted 2,4-thiazolidinediones. | Bioorganic & medicinal chemistry letters 20080315 |
| Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080315 |
| Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. | Breast cancer research and treatment 20080301 |
| Fatty acid-induced mitochondrial uncoupling in adipocytes is not a promising target for treatment of insulin resistance unless adipocyte oxidative capacity is increased. | Diabetologia 20080301 |
| 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. | Diabetes research and clinical practice 20080301 |
| Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. | Clinical journal of the American Society of Nephrology : CJASN 20080301 |
| Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. | International journal of clinical practice. Supplement 20080301 |
| Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis. | Journal of cardiovascular pharmacology 20080301 |
| Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. | The British journal of nutrition 20080201 |
| Skeletal consequences of thiazolidinedione therapy. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080201 |
| Antiproteinuric and anti-inflammatory effects of thiazolidinedione. | Nephrology (Carlton, Vic.) 20080201 |
| Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. | Nephrology (Carlton, Vic.) 20080201 |
| The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. | International journal of clinical practice 20080201 |
| [One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study]. | Annales d'endocrinologie 20080201 |
| Oral antidiabetic medication adherence and glycemic control in managed care. | The American journal of managed care 20080201 |
| The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20080201 |
| Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. | Hypertension research : official journal of the Japanese Society of Hypertension 20080201 |
| Synthesis of polymeric thiazolidinedione and fibrate conjugates. | Archives of pharmacal research 20080201 |
| Pharmacogenomics of metabolic effects of rosiglitazone. | Pharmacogenomics 20080201 |
| Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes. | Vascular health and risk management 20080201 |
| Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. | Diabetes & metabolism 20080201 |
| DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? | Diabetes & metabolism 20080201 |
| (Z)-5-(4-Fluoro-benzyl-idene)-1,3-thia-zolidine-2,4-dione. | Acta crystallographica. Section E, Structure reports online 20080201 |
| The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. | Molecular pharmacology 20080101 |
| The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. | International journal of clinical practice 20080101 |
| Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. | Diabetes, obesity & metabolism 20080101 |
| Update: vildagliptin for the treatment of Type 2 diabetes. | Expert opinion on investigational drugs 20080101 |
| Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. | International journal of oncology 20080101 |
| Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. | European heart journal 20080101 |
| Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. | Arthritis research & therapy 20080101 |
| COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. | BMC cancer 20080101 |
| Common crossroads in diabetes management. | Osteopathic medicine and primary care 20080101 |
| Peroxisome proliferator activated receptors and lipoprotein metabolism. | PPAR research 20080101 |
| Role of the peroxisome proliferator-activated receptors, adenosine monophosphate-activated kinase, and adiponectin in the ovary. | PPAR research 20080101 |
| PPAR Agonists and Cardiovascular Disease in Diabetes. | PPAR research 20080101 |
| The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. | PPAR research 20080101 |
| Peroxisome proliferator-activated receptors as mediators of phthalate-induced effects in the male and female reproductive tract: epidemiological and experimental evidence. | PPAR research 20080101 |
| Hexarelin Signaling to PPARgamma in Metabolic Diseases. | PPAR research 20080101 |
| Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases. | PPAR research 20080101 |
| PPAR Action in Human Placental Development and Pregnancy and Its Complications. | PPAR research 20080101 |
| PPAR-gamma in the Cardiovascular System. | PPAR research 20080101 |
| Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. | Cardiovascular diabetology 20080101 |
| PPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility. | PPAR research 20080101 |
| Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. | PPAR research 20080101 |
| Cryptochrome and Period Proteins Are Regulated by the CLOCK/BMAL1 Gene: Crosstalk between the PPARs/RXRalpha-Regulated and CLOCK/BMAL1-Regulated Systems. | PPAR research 20080101 |
| Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice. | Reproductive biology and endocrinology : RB&E 20080101 |
| Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation. | PPAR research 20080101 |
| PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches. | PPAR research 20080101 |
| Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). | Antiviral therapy 20080101 |
| Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy. | American journal of nephrology 20080101 |
| Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). | Cardiovascular diabetology 20080101 |
| The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. | BMC medical genomics 20080101 |
| Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. | PPAR research 20080101 |
| Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists. | PPAR research 20080101 |
| Rosiglitazone-induced anasarca without heart failure: capillary leakage? | Hormones (Athens, Greece) 20080101 |
| Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms. | PloS one 20080101 |
| PPAR Ligands for Cancer Chemoprevention. | PPAR research 20080101 |
| The Critical Role of PPARgamma in Human Malignant Melanoma. | PPAR research 20080101 |
| Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits. | Thrombosis journal 20080101 |
| Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. | Arthritis research & therapy 20080101 |
| Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. | Cardiovascular diabetology 20080101 |
| PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors. | PPAR research 20080101 |
| Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer. | PPAR research 20080101 |
| PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies. | PPAR research 20080101 |
| Fat and beyond: the diverse biology of PPARgamma. | Annual review of biochemistry 20080101 |
| A combination of nutriments improves mitochondrial biogenesis and function in skeletal muscle of type 2 diabetic Goto-Kakizaki rats. | PloS one 20080101 |
| Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. | The Diabetes educator 20080101 |
| Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. | PPAR research 20080101 |
| Statins but not thiazolidinediones attenuate albumin-mediated chemokine production by proximal tubular cells independently of endocytosis. | American journal of nephrology 20080101 |
| Screening for PPAR Responsive Regulatory Modules in Cancer. | PPAR research 20080101 |
| Peroxisome proliferator-activated receptors and progression of colorectal cancer. | PPAR research 20080101 |
| Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. | PPAR research 20080101 |
| Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. | PloS one 20080101 |
| PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate. | PPAR research 20080101 |
| A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer. | PPAR research 20080101 |
| Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template. | PPAR research 20080101 |
| Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. | Cardiovascular diabetology 20080101 |
| Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. | Drugs & aging 20080101 |
| The Role of PPARs in Cancer. | PPAR research 20080101 |
| Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-gamma Agonists. | PPAR research 20080101 |
| PPARgamma and MEK Interactions in Cancer. | PPAR research 20080101 |
| Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. | BMC medical genetics 20080101 |
| PPAR-gamma: Therapeutic Potential for Multiple Sclerosis. | PPAR research 20080101 |
| The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer. | PPAR research 20080101 |
| PPARgamma and Apoptosis in Cancer. | PPAR research 20080101 |
| A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer Biology. | PPAR research 20080101 |
| Pathophysiological Roles of PPARgamma in Gastrointestinal Epithelial Cells. | PPAR research 20080101 |
| The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. | PPAR research 20080101 |
| Do PPARgamma Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the Tumor? | PPAR research 20080101 |
| The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations. | BMC developmental biology 20080101 |
| Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? | PPAR research 20080101 |
| PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes. | PPAR research 20080101 |
| Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. | PPAR research 20080101 |
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. | Journal of managed care pharmacy : JMCP 20080101 |
| Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells. | PPAR research 20080101 |
| Performing meta-analysis with incomplete statistical information in clinical trials. | BMC medical research methodology 20080101 |
| Chondrosarcoma and peroxisome proliferator-activated receptor. | PPAR research 20080101 |
| A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development. | Nutrition & metabolism 20080101 |
| Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation. | Thrombosis journal 20080101 |
| Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. | PPAR research 20080101 |
| The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer. | PPAR research 20080101 |
| The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer. | PPAR research 20080101 |
| PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive Agents. | PPAR research 20080101 |
| Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. | PPAR research 20080101 |
| CXCR4 in Cancer and Its Regulation by PPARgamma. | PPAR research 20080101 |
| To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. | PPAR research 20080101 |
| TZDs and Bone: A Review of the Recent Clinical Evidence. | PPAR research 20080101 |
| Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. | BMC neurology 20080101 |
| PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion. | PPAR research 20080101 |
| Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. | BMC molecular biology 20080101 |
| Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects. | Cardiovascular diabetology 20080101 |
| Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. | Archivum immunologiae et therapiae experimentalis 20080101 |
| Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. | BMC endocrine disorders 20080101 |
| Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. | Drugs 20080101 |
| Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary. | Health and quality of life outcomes 20080101 |
| PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities. | PPAR research 20080101 |
| The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. | PPAR research 20080101 |
| Membrane potential controls adipogenic and osteogenic differentiation of mesenchymal stem cells. | PloS one 20080101 |
| The Role of PPARs in the Endothelium: Implications for Cancer Therapy. | PPAR research 20080101 |
| Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. | Arthritis research & therapy 20080101 |
| Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. | Molecular cancer 20080101 |
| Clinical Use of PPARgamma Ligands in Cancer. | PPAR research 20080101 |
| Peripheral mononuclear cell resistin mRNA expression is increased in type 2 diabetic women. | Mediators of inflammation 20080101 |
| Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. | Human genomics 20080101 |
| PPAR-delta in Vascular Pathophysiology. | PPAR research 20080101 |
| The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. | PPAR research 20080101 |
| Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. | PPAR research 20080101 |
| Protective Actions of PPAR-gamma Activation in Renal Endothelium. | PPAR research 20080101 |
| Peroxisome proliferator-activated receptors in diabetic nephropathy. | PPAR research 20080101 |
| Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer. | PPAR research 20080101 |
| PPARgamma in Kidney Physiology and Pathophysiology. | PPAR research 20080101 |
| Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities. | PPAR research 20080101 |
| Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. | International journal of diabetes in developing countries 20080101 |
| Effect of butanol fraction from Cassia tora L. seeds on glycemic control and insulin secretion in diabetic rats. | Nutrition research and practice 20080101 |
| Correlation between changes in blood pressure with insulin resistance in type 2 diabetes mellitus with four weeks of pioglitazone therapy. | International journal of diabetes in developing countries 20080101 |
| Relationship between arachidonic acid pathway and human renal cell carcinoma. | OncoTargets and therapy 20080101 |
| QSAR Study on Thiazolidine-2,4-dione Derivatives for Antihyperglycemic Activity. | Indian journal of pharmaceutical sciences 20080101 |
| Adipose inflammation: cause or consequence of obesity-related insulin resistance. | Diabetes, metabolic syndrome and obesity : targets and therapy 20080101 |
| Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. | Open medicine : a peer-reviewed, independent, open-access journal 20080101 |
| Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats. | Clinical medicine. Oncology 20080101 |
| Therapeutic Potential of PPARγ Activation in Stroke. | PPAR research 20080101 |
| Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications. | Pediatric nephrology (Berlin, Germany) 20071201 |
| PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo. | American journal of physiology. Endocrinology and metabolism 20071201 |
| Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. | Kidney international 20071201 |
| Effects of thiazolidinediones on bone loss and fracture. | The Annals of pharmacotherapy 20071201 |
| Diabetes mellitus, bone mineral density, and fracture risk. | Current opinion in endocrinology, diabetes, and obesity 20071201 |
| Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? | Kidney international 20071201 |
| Clinical predictors of glycosylated hemoglobin response to thiazolidinedione therapy. | Diabetes technology & therapeutics 20071201 |
| Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. | Kidney international 20071201 |
| A review of nateglinide in the management of patients with type 2 diabetes. | Vascular health and risk management 20071201 |
| Endothelial dysfunction in diabetes mellitus. | Vascular health and risk management 20071201 |
| A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. | Vascular health and risk management 20071201 |
| Rationale for multiple risk intervention: the need to move from theory to practice. | Vascular health and risk management 20071201 |
| Treatment of non-alcoholic fatty liver disease. | Therapeutics and clinical risk management 20071201 |
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | Current neuropharmacology 20071201 |
| Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. | Atherosclerosis 20071101 |
| The cystic fibrosis transmembrane recruiter the alter ego of CFTR as a multi-kinase anchor. | Pflugers Archiv : European journal of physiology 20071101 |
| A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus. | American journal of physiology. Heart and circulatory physiology 20071101 |
| Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. | Current medical research and opinion 20071101 |
| Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. | Metabolism: clinical and experimental 20071101 |
| NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance. | The Journal of biological chemistry 20071026 |
| Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma. | The Journal of biological chemistry 20071012 |
| Pioglitazone ameliorates endothelial dysfunction in obese rats with nephropathy. | Biochemical and biophysical research communications 20071005 |
| PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. | Fertility and sterility 20071001 |
| Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. | Diabetes care 20071001 |
| Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071001 |
| The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. | Hepatology (Baltimore, Md.) 20071001 |
| Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. | Pharmacotherapy 20071001 |
| Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20071001 |
| 15-deoxy-Delta 12,14-ProstaglandinJ2 regulates dedifferentiation through peroxisome proliferator-activated receptor-gamma-dependent pathway but not COX-2 expression in articular chondrocytes. | Journal of Korean medical science 20071001 |
| Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. | Archives of pharmacal research 20071001 |
| Optimizing combination treatment in the management of type 2 diabetes. | Vascular health and risk management 20071001 |
| A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. | Vascular health and risk management 20071001 |
| Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. | Diabetes research and clinical practice 20070901 |
| Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. | Molecular pharmacology 20070901 |
| Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. | Diabetologia 20070901 |
| Effects of pioglitazone on lipid and lipoprotein metabolism. | Diabetes, obesity & metabolism 20070901 |
| Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase. | The Journal of endocrinology 20070901 |
| A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. | Endocrine-related cancer 20070901 |
| Synthesis and biological activity of 5-{4-[2-(methyl-p-substituted phenylamino)ethoxy]benzyl}thiazolidine-2,4-diones. | Archives of pharmacal research 20070901 |
| Variation in antidiabetic medication intensity among Medicare beneficiaries with diabetes mellitus. | The American journal of geriatric pharmacotherapy 20070901 |
| Pathogenesis of Alzheimer's disease. | Clinical interventions in aging 20070901 |
| Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureas. | Managed care interface 20070901 |
| The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster. | The Journal of biological chemistry 20070817 |
| Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators. | Bioorganic & medicinal chemistry letters 20070815 |
| Cytosolic aspartate aminotransferase, a new partner in adipocyte glyceroneogenesis and an atypical target of thiazolidinedione. | The Journal of biological chemistry 20070810 |
| Prepartum 2,4-thiazolidinedione alters metabolic dynamics and dry matter intake of dairy cows. | Journal of dairy science 20070801 |
| Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. | Pharmacotherapy 20070801 |
| Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. | The American journal of managed care 20070801 |
| Pharmacogenetics of thiazolidinedione therapy. | Pharmacogenomics 20070801 |
| Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy. | Clinical therapeutics 20070801 |
| PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. | Vascular health and risk management 20070801 |
| Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus. | Vascular health and risk management 20070801 |
| Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. | Vascular health and risk management 20070801 |
| Alkynyl ruthenium colorimetric sensors: optimizing the selectivity toward fluoride anion. | Inorganic chemistry 20070723 |
| Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. | The Journal of biological chemistry 20070706 |
| The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. | Journal of the American College of Cardiology 20070703 |
| Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. | Diabetes care 20070701 |
| The effect of moderate alcohol consumption on adiponectin oligomers and muscle oxidative capacity: a human intervention study. | Diabetologia 20070701 |
| Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. | American heart journal 20070701 |
| Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. | Diabetes, obesity & metabolism 20070701 |
| Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. | Diabetes, obesity & metabolism 20070701 |
| Pioglitazone hydrochloride/glimepiride. | Drugs of today (Barcelona, Spain : 1998) 20070701 |
| Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20070701 |
| [Doubts as to the cardiovascular safety of rosiglitazone]. | Nederlands tijdschrift voor geneeskunde 20070630 |
| Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice. | Life sciences 20070613 |
| Wnt-signaling is maintained and adipogenesis inhibited by TNFalpha but not MCP-1 and resistin. | Biochemical and biophysical research communications 20070608 |
| Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. | Molecular pharmacology 20070601 |
| Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. | Diabetes care 20070601 |
| The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. | Molecular pharmacology 20070601 |
| A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20070601 |
| Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. | Molecular pharmacology 20070601 |
| Rosiglitazone RECORD study: glucose control outcomes at 18 months. | Diabetic medicine : a journal of the British Diabetic Association 20070601 |
| Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? | Diabetes care 20070601 |
| Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. | International journal of clinical practice. Supplement 20070601 |
| An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity. | Journal of medicinal chemistry 20070531 |
| Effect of glucolipotoxicity and rosiglitazone upon insulin secretion. | Biochemical and biophysical research communications 20070511 |
| Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. | Pharmacoepidemiology and drug safety 20070501 |
| Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. | American journal of physiology. Endocrinology and metabolism 20070501 |
| Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton. | Bioorganic & medicinal chemistry 20070501 |
| Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner. | International journal of oncology 20070501 |
| Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. | Cellular and molecular life sciences : CMLS 20070501 |
| Effects of growth hormone and pioglitazone in viscerally obese adults with impaired glucose tolerance: a factorial clinical trial. | PLoS clinical trials 20070501 |
| Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. | British journal of clinical pharmacology 20070501 |
| The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. | Cell metabolism 20070501 |
| The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. | Journal of clinical immunology 20070501 |
| [PPARgamma and metabolic syndrome]. | Rinsho byori. The Japanese journal of clinical pathology 20070501 |
| The Anti-Obesity Effect of the Palatinose-Based Formula Inslow is Likely due to an Increase in the Hepatic PPAR-alpha and Adipocyte PPAR-gamma Gene Expressions. | Journal of clinical biochemistry and nutrition 20070501 |
| Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. | Yonsei medical journal 20070430 |
| Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway. | The Journal of biological chemistry 20070406 |
| Summaries for patients. Exenatide therapy for type 2 diabetes. | Annals of internal medicine 20070403 |
| The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. | Annals of internal medicine 20070403 |
| Exenatide in combination therapy: small study, big market, and many unanswered questions. | Annals of internal medicine 20070403 |
| Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. | American journal of physiology. Renal physiology 20070401 |
| Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. | The Journal of clinical endocrinology and metabolism 20070401 |
| Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes. | Molecular endocrinology (Baltimore, Md.) 20070401 |
| The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. | The Journal of clinical endocrinology and metabolism 20070401 |
| Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. | Expert opinion on investigational drugs 20070401 |
| Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. | Journal of immunology (Baltimore, Md. : 1950) 20070401 |
| PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. | PLoS genetics 20070401 |
| Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. | Vascular health and risk management 20070401 |
| Thiazolidinediones and vascular damage. | Current opinion in endocrinology, diabetes, and obesity 20070401 |
| Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. | The Journal of pharmacology and experimental therapeutics 20070301 |
| Synthesis of O-prenylated and O-geranylated derivatives of 5-benzylidene2,4-thiazolidinediones and evaluation of their free radical scavenging activity as well as effect on some phase II antioxidant/detoxifying enzymes. | Bioorganic & medicinal chemistry letters 20070301 |
| Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression. | Diabetologia 20070301 |
| Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. | Diabetes, obesity & metabolism 20070301 |
| Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. | Nature medicine 20070301 |
| Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. | Life sciences 20070227 |
| Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. | American journal of physiology. Endocrinology and metabolism 20070201 |
| Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. | The Journal of clinical endocrinology and metabolism 20070201 |
| Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20070201 |
| Rosiglitazone: rosy news for a thiazolidinedione. | Expert opinion on pharmacotherapy 20070201 |
| [Complex dietary measures and pharmacotherapy for metabolic syndrome]. | Der Internist 20070201 |
| Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. | Diabetes technology & therapeutics 20070201 |
| Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. | Journal of neurosurgery 20070201 |
| The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance. | Biochemistry and cell biology = Biochimie et biologie cellulaire 20070201 |
| Inhaled human insulin (Exubera): clinical profile and patient considerations. | Vascular health and risk management 20070201 |
| Effect of thiazolidinediones on bile acid transport in rat liver. | Life sciences 20070130 |
| Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. | Diabetes research and clinical practice 20070101 |
| Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. | Neurochemical research 20070101 |
| Weight changes following the initiation of new anti-hyperglycaemic therapies. | Diabetes, obesity & metabolism 20070101 |
| Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070101 |
| Effect of pioglitazone treatment on behavioral symptoms in autistic children. | Journal of neuroinflammation 20070101 |
| Walking behaviour and glycemic control in type 2 diabetes: seasonal and gender differences--study design and methods. | Cardiovascular diabetology 20070101 |
| Effect of thiazolidinedione on the proliferation of bovine retinal endothelial cells stimulated by vascular endothelial cell growth factor. | Japanese journal of ophthalmology 20070101 |
| Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. | Arthritis research & therapy 20070101 |
| PPARs in the Control of Uncoupling Proteins Gene Expression. | PPAR research 20070101 |
| Genetic manipulations of PPARs: effects on obesity and metabolic disease. | PPAR research 20070101 |
| Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. | PPAR research 20070101 |
| The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. | PPAR research 20070101 |
| 'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. | PPAR research 20070101 |
| Metabolic Functions of Peroxisome Proliferator-Activated Receptor beta/delta in Skeletal Muscle. | PPAR research 20070101 |
| The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. | Molecular cancer 20070101 |
| A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. | Osteopathic medicine and primary care 20070101 |
| Thiazolidinedione induced thyroid associated orbitopathy. | BMC ophthalmology 20070101 |
| LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome. | PloS one 20070101 |
| An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. | BMC gastroenterology 20070101 |
| Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats. | Cardiovascular diabetology 20070101 |
| Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. | BMC medicine 20070101 |
| Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2. | PPAR research 20070101 |
| Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. | Cardiovascular diabetology 20070101 |
| Sitagliptin: a novel drug for the treatment of type 2 diabetes. | Cardiology in review 20070101 |
| The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. | PPAR research 20070101 |
| PPARs and Adipose Cell Plasticity. | PPAR research 20070101 |
| The Role of PPARs in Lung Fibrosis. | PPAR research 20070101 |
| The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. | PPAR research 20070101 |
| 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. | Breast cancer research : BCR 20070101 |
| Beneficial effects of pioglitazone on cholangiohepatitis induced by bile duct carcinoma. | Internal medicine (Tokyo, Japan) 20070101 |
| Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions. | Cardiovascular diabetology 20070101 |
| Variants in the FFAR1 gene are associated with beta cell function. | PloS one 20070101 |
| Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. | PPAR research 20070101 |
| Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. | BMC cancer 20070101 |
| Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. | Respiratory research 20070101 |
| Rosiglitazone : a review of its use in type 2 diabetes mellitus. | Drugs 20070101 |
| Stimulatory Effects of Peroxisome Proliferator-Activated Receptor-gamma on Fcgamma Receptor-Mediated Phagocytosis by Alveolar Macrophages. | PPAR research 20070101 |
| Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. | PPAR research 20070101 |
| Is PPARbeta/delta a Retinoid Receptor? | PPAR research 20070101 |
| Peroxisome proliferator-activated receptors in lung cancer. | PPAR research 20070101 |
| Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. | Mediators of inflammation 20070101 |
| PPARgamma2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells. | PPAR research 20070101 |
| Energy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone. | PPAR research 20070101 |
| The Functions of PPARs in Aging and Longevity. | PPAR research 20070101 |
| Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. | Oncology 20070101 |
| Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. | Experimental and clinical cardiology 20070101 |
| Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma. | Gene regulation and systems biology 20070101 |
| Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. | Core evidence 20070101 |
| Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. | Core evidence 20070101 |
| [Experiences of the DREAM trial]. | Orvosi hetilap 20061231 |
| Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents. | Bioorganic & medicinal chemistry letters 20061201 |
| Pioglitazone increases gallbladder volume in insulin-resistant obese mice. | The Journal of surgical research 20061201 |
| Pattern of thiazolidinedione exposures reported to Texas poison centers during 1998-2004. | Journal of toxicology and environmental health. Part A 20061201 |
| Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone. | Environmental and molecular mutagenesis 20061201 |
| Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. | The Journal of clinical investigation 20061201 |
| Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. | Diabetes & vascular disease research 20061201 |
| The pharmacokinetics of pioglitazone in Thai healthy subjects. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20061201 |
| Metabolic domino: new concept in lifestyle medicine. | Drugs of today (Barcelona, Spain : 1998) 20061201 |
| Alteration of vascular reactivity in diabetic human mammary artery and the effects of thiazolidinediones. | The Journal of pharmacy and pharmacology 20061201 |
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. | The New England journal of medicine 20061130 |
| Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. | International journal of cancer 20061115 |
| The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. | Journal of lipid research 20061101 |
| Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. | Expert opinion on investigational drugs 20061101 |
| Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. | Clinical and experimental pharmacology & physiology 20061101 |
| Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. | Metabolism: clinical and experimental 20061101 |
| Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials. | Current medical research and opinion 20061101 |
| Oral combination therapy with thiazolidinediones in type 2 diabetes. | The American journal of managed care 20061101 |
| AMPK regulation of the growth of cultured human keratinocytes. | Biochemical and biophysical research communications 20061020 |
| Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. | British journal of cancer 20061009 |
| Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. | British journal of cancer 20061009 |
| Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. | Bone 20061001 |
| Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. | Cell metabolism 20061001 |
| Metabolism of troglitazone in hepatocytes isolated from experimentally induced diabetic rats. | The Journal of pharmacy and pharmacology 20061001 |
| Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. | Drug metabolism and pharmacokinetics 20061001 |
| [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease]. | Revue medicale de Liege 20061001 |
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. | Lancet (London, England) 20060923 |
| SB-271258, a major metabolite in the dog of the thiazolidinedione, rosiglitazone, stimulates protein synthesis in re-differentiated rat cardiomyocytes in vitro. | Toxicology in vitro : an international journal published in association with BIBRA 20060901 |
| Thiazolidinedione use and bone loss in older diabetic adults. | The Journal of clinical endocrinology and metabolism 20060901 |
| Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans. | Drug metabolism and disposition: the biological fate of chemicals 20060901 |
| Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione. | Diabetologia 20060901 |
| Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. | Diabetes, obesity & metabolism 20060901 |
| PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. | Clinical endocrinology 20060901 |
| Endothelial dysfunction and its role in diabetic vascular disease. | Endocrinology and metabolism clinics of North America 20060901 |
| [What is the most effective approach to the reduction of cardiovascular risk in type-2 diabetes mellitus?]. | Orvosi hetilap 20060806 |
| Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells. | Journal of neurochemistry 20060801 |
| Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells. | International journal of oncology 20060801 |
| Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. | Diabetes 20060801 |
| Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. | Chemical research in toxicology 20060801 |
| Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801 |
| Development of small-molecule cyclin D1-ablative agents. | Journal of medicinal chemistry 20060727 |
| FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. | The Journal of biological chemistry 20060721 |
| Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. | European journal of clinical pharmacology 20060701 |
| Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. | Vascular pharmacology 20060701 |
| Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. | Diabetes care 20060701 |
| Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar? | Pharmacotherapy 20060701 |
| Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. | Clinical endocrinology 20060701 |
| Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. | Journal of medicinal chemistry 20060629 |
| Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. | Science (New York, N.Y.) 20060616 |
| RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. | Molecular and cellular endocrinology 20060607 |
| Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060601 |
| Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. | Endocrine journal 20060601 |
| Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. | Experimental gerontology 20060601 |
| Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. | Endocrine-related cancer 20060601 |
| Thiazolidinedione derivatives in type 2 diabetes mellitus. | The Netherlands journal of medicine 20060601 |
| Growth-inhibitory action of melatonin and thiazolidinedione derivative CGP 52608 on murine 16/C breast cancer cells. | Neuro endocrinology letters 20060601 |
| Can thiazolidinediones delay disease progression in type 2 diabetes? | Current medical research and opinion 20060601 |
| Synthesis and pharmacological activity of 2-(substituted)-3-{2-[(4-phenyl-4-cyano)piperidino]ethyl}-1,3-thiazolidin-4-ones. | Chemical biology & drug design 20060601 |
| Metabolic syndrome, inflammation and atherosclerosis. | Vascular health and risk management 20060601 |
| Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. | Toxicology 20060515 |
| Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. | Journal of medicinal chemistry 20060504 |
| Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. | Molecular pharmacology 20060501 |
| Peroxisome proliferator-activated receptor gamma regulates expression of signal transducer and activator of transcription 5A. | Experimental cell research 20060501 |
| Rosiglitazone-induced immune thrombocytopenia. | Platelets 20060501 |
| A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. | Molecular cancer therapeutics 20060501 |
| Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. | Biochemical pharmacology 20060428 |
| Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. | Oncogene 20060413 |
| The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20060301 |
| Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes. | Prostaglandins, leukotrienes, and essential fatty acids 20060301 |
| Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. | European journal of clinical pharmacology 20060301 |
| Managing diabetic nephropathy: recent studies. | Current opinion in nephrology and hypertension 20060301 |
| Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. | The American journal of cardiology 20060301 |
| What has prevented the expansion of insulin sensitisers? | Expert opinion on investigational drugs 20060301 |
| Haplotype structures and large-scale association testing of the 5' AMP-activated protein kinase genes PRKAA2, PRKAB1, and PRKAB2 [corrected] with type 2 diabetes. | Diabetes 20060301 |
| Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. | Diabetes care 20060301 |
| Synthesis and PPAR-gamma ligand-binding activity of the new series of 2'-hydroxychalcone and thiazolidinedione derivatives. | Chemical & pharmaceutical bulletin 20060301 |
| 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor. | The Journal of endocrinology 20060301 |
| Therapy of NAFLD: insulin sensitizing agents. | Journal of clinical gastroenterology 20060301 |
| Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. | Current medical research and opinion 20060301 |
| C/EBPalpha-dependent induction of glutathione S-transferase zeta/maleylacetoacetate isomerase (GSTzeta/MAAI) expression during the differentiation of mouse fibroblasts into adipocytes. | Biochemical and biophysical research communications 20060217 |
| Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. | Endocrinology 20060201 |
| Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. | Bioorganic & medicinal chemistry letters 20060201 |
| Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. | Diabetes 20060201 |
| Improving metabolic control leads to better working memory in adults with type 2 diabetes. | Diabetes care 20060201 |
| High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. | Diabetes technology & therapeutics 20060201 |
| Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. | Journal of clinical pharmacy and therapeutics 20060201 |
| Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. | Bone 20060101 |
| Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. | Human reproduction (Oxford, England) 20060101 |
| Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. | Human reproduction (Oxford, England) 20060101 |
| Pioglitazone increases non-esterified fatty acid clearance in upper body obesity. | Diabetologia 20060101 |
| Attenuation of experimental colonic injury by thiazolidinedione agents. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20060101 |
| Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. | American journal of physiology. Regulatory, integrative and comparative physiology 20060101 |
| THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. | Arthritis research & therapy 20060101 |
| Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. | Diabetes, obesity & metabolism 20060101 |
| Effect of rifampicin on the pharmacokinetics of pioglitazone. | British journal of clinical pharmacology 20060101 |
| Receptor Ck-dependent signaling regulates hTERT gene transcription. | BMC cell biology 20060101 |
| Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. | Annals of clinical microbiology and antimicrobials 20060101 |
| The in vitro real-time oscillation monitoring system identifies potential entrainment factors for circadian clocks. | BMC molecular biology 20060101 |
| PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. | BMC cancer 20060101 |
| Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening. | International journal of toxicology 20060101 |
| Nuclear receptor corepressors and PPARgamma. | Nuclear receptor signaling 20060101 |
| The impact of cognitive functioning on mortality and the development of functional disability in older adults with diabetes: the second longitudinal study on aging. | BMC geriatrics 20060101 |
| Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities. | Treatments in endocrinology 20060101 |
| Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus. | Journal of intensive care medicine 20060101 |
| Effect of troglitazone on serum gamma-glutamyltransferase activity and plasma t-PA/PAI-1 complex in type 2 diabetic patients. | Arzneimittel-Forschung 20060101 |
| Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study. | BMC endocrine disorders 20060101 |
| Modulation of adipocyte lipogenesis by octanoate: involvement of reactive oxygen species. | Nutrition & metabolism 20060101 |
| Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. | BMC medical imaging 20060101 |
| The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. | Journal of diabetes and its complications 20060101 |
| Treatment of type 2 diabetes. Use of fixed-dose oral combinations. | Postgraduate medicine 20060101 |
| Molecular electrostatic potentials in the design of dendrimers for the delivery of glitazones. | Journal of nanoscience and nanotechnology 20060101 |
| Synthesis and antidiabetic activity of novel 2,4-thiazolidinedione derivatives containing a thiazole ring. | Arzneimittel-Forschung 20060101 |
| ADDP and PS-PPh3: an efficient Mitsunobu protocol for the preparation of pyridine ether PPAR agonists. | Beilstein journal of organic chemistry 20060101 |
| Incorporating genome-scale tools for studying energy homeostasis. | Nutrition & metabolism 20060101 |
| Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101 |
| Resolving the Two 'Bony' Faces of PPAR-gamma. | PPAR research 20060101 |
| Fine-Tuning Reception in the Bone: PPARgamma and Company. | PPAR research 20060101 |
| Peroxisome Proliferator-Activated Receptor-gamma Promotes Adipogenic Changes in Growth Plate Chondrocytes In Vitro. | PPAR research 20060101 |
| The Genetics of PPARG and the Skeleton. | PPAR research 20060101 |
| Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). | PPAR research 20060101 |
| The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. | The review of diabetic studies : RDS 20060101 |
| BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application. | The Journal of pharmacology and experimental therapeutics 20051201 |
| Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. | Toxicology 20051201 |
| Oral agents in managing diabetes mellitus in children and adolescents. | Pediatric clinics of North America 20051201 |
| Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. | Diabetes care 20051201 |
| Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. | Journal of cardiovascular pharmacology 20051201 |
| Optimal lipid modification: the rationale for combination therapy. | Vascular health and risk management 20051201 |
| [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance]. | Zhonghua yi xue za zhi 20051116 |
| Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. | The Journal of clinical endocrinology and metabolism 20051101 |
| Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. | Diabetes, obesity & metabolism 20051101 |
| Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. | Hypertension research : official journal of the Japanese Society of Hypertension 20051101 |
| Drug-induced weight gain. | Timely topics in medicine. Cardiovascular diseases 20051028 |
| [Insulin resistance: the adipose tissue in the focus]. | Orvosi hetilap 20051023 |
| Ligand recognition by RAR and RXR receptors: binding and selectivity. | Journal of medicinal chemistry 20051006 |
| Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. | Endocrinology 20051001 |
| The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats. | Metabolism: clinical and experimental 20051001 |
| Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20051001 |
| Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. | Pharmacotherapy 20051001 |
| Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. | Journal of thrombosis and haemostasis : JTH 20051001 |
| Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. | Hepatology research : the official journal of the Japan Society of Hepatology 20051001 |
| [The effects of thiazolidinedione from the cardiologic viewpoint]. | Medizinische Monatsschrift fur Pharmazeuten 20051001 |
| Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. | Clinical therapeutics 20051001 |
| Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. | Clinical therapeutics 20051001 |
| Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. | Toxicology 20050915 |
| Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. | European journal of medicinal chemistry 20050901 |
| In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I. | Bioorganic & medicinal chemistry letters 20050901 |
| Impact of thiazolidinedione therapy on atherogenesis. | Current atherosclerosis reports 20050901 |
| The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. | Journal of neuropathology and experimental neurology 20050901 |
| Characteristics of type 2 diabetes in terms of insulin resistance in Korea. | Yonsei medical journal 20050831 |
| Determination of urinary Myo-/chiro-inositol ratios from Korean diabetes patients. | Yonsei medical journal 20050831 |
| Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. | World journal of gastroenterology 20050828 |
| [Triple oral therapy in type 2 diabetes]. | Revue medicale suisse 20050824 |
| Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. | Current hypertension reports 20050801 |
| Drug-induced weight gain. | Drugs of today (Barcelona, Spain : 1998) 20050801 |
| Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? | Biochemical pharmacology 20050715 |
| 6-Aryl-4-methylsulfanyl-2H-pyran-2-one-3-carbonitriles as PPAR-gamma activators. | Bioorganic & medicinal chemistry letters 20050715 |
| Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20050601 |
| Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRbeta(R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone. | Bioorganic & medicinal chemistry 20050601 |
| Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. | Acta pharmacologica Sinica 20050601 |
| Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. | Endocrine-related cancer 20050601 |
| Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. | Journal of Korean medical science 20050601 |
| Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. | Endocrine journal 20050601 |
| Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. | Endocrine journal 20050601 |
| Thiazolidinediones in type 2 diabetes--have they lived up to expectations? | Journal of the Indian Medical Association 20050601 |
| The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. | The Journal of pharmacology and experimental therapeutics 20050501 |
| Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. | Molecular pharmacology 20050501 |
| Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. | Diabetologia 20050501 |
| Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. | Chemical research in toxicology 20050501 |
| Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. | Clinical pharmacology and therapeutics 20050501 |
| Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? | Diabetes & vascular disease research 20050501 |
| Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20050401 |
| Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. | Diabetes 20050401 |
| [PPARs as molecular targets for drug discovery]. | Nihon rinsho. Japanese journal of clinical medicine 20050401 |
| [Polycystic ovary syndrome]. | Nihon rinsho. Japanese journal of clinical medicine 20050401 |
| Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. | Journal of cardiology 20050401 |
| Adherence to oral hypoglycemic agents in Hawaii. | Preventing chronic disease 20050401 |
| Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. | The Journal of biological chemistry 20050318 |
| PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. | American journal of physiology. Heart and circulatory physiology 20050301 |
| Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. | Diabetes, obesity & metabolism 20050301 |
| Thiazolidinedione (pioglitazone) blocks P. gingivalis- and F. nucleatum, but not E. coli, lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) production in adipocytes. | Journal of dental research 20050301 |
| Thiazolidinediones and cardiovascular disease. | Current atherosclerosis reports 20050301 |
| Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus. | Yonsei medical journal 20050227 |
| Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. | The Journal of biological chemistry 20050225 |
| Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. | Genes & development 20050215 |
| Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. | Circulation 20050208 |
| Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. | Toxicological sciences : an official journal of the Society of Toxicology 20050201 |
| Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism. | Atherosclerosis 20050201 |
| Case-based study: from prediabetes to complications--opportunities for prevention. | PLoS medicine 20050201 |
| [Selection of oral antidiabetic drugs]. | Nihon rinsho. Japanese journal of clinical medicine 20050201 |
| The utility of oral diabetes medications in type 2 diabetes of the young. | Current diabetes reviews 20050201 |
| Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. | British journal of cancer 20050117 |
| Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. | Toxicology letters 20050115 |
| Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. | The Journal of pharmacology and experimental therapeutics 20050101 |
| The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. | British journal of clinical pharmacology 20050101 |
| Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. | Drugs 20050101 |
| Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. | Diabetologia 20050101 |
| Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. | Diabetes, obesity & metabolism 20050101 |
| Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. | Lipids in health and disease 20050101 |
| Oral antidiabetic agents: current role in type 2 diabetes mellitus. | Drugs 20050101 |
| Enhanced insulin secretion from engineered 3T3-L1 preadipocytes by induction of cellular differentiation. | Molecular and cellular biochemistry 20050101 |
| PPAR gamma, 10 years later. | Biochimie 20050101 |
| Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. | Biochimie 20050101 |
| Pharmacologic management of Cushing syndrome : new targets for therapy. | Treatments in endocrinology 20050101 |
| Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. | BMC medical genetics 20050101 |
| Enantiomer ratio of MK-0767 in humans and nonclinical species. | Rapid communications in mass spectrometry : RCM 20050101 |
| Diabetes and cardiovascular risk markers. | Current medical research and opinion 20050101 |
| Drug interactions of clinical importance with antihyperglycaemic agents: an update. | Drug safety 20050101 |
| [Towards a tripple oral therapy in the pharmacological treatment of type 2 diabetes?]. | Revue medicale de Liege 20050101 |
| Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. | Treatments in endocrinology 20050101 |
| Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. | Reproductive biology and endocrinology : RB&E 20050101 |
| Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis. | Respiratory research 20050101 |
| Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. | Skinmed 20050101 |
| Unliganded RXR acts as an inhibitory factor on troglitazone-induced activation. | Life sciences 20041231 |
| Requirements for pYXXM motifs in Cbl for binding to the p85 subunit of phosphatidylinositol 3-kinase and Crk, and activation of atypical protein kinase C and glucose transport during insulin action in 3T3/L1 adipocytes. | Biochemistry 20041214 |
| Insulin substrates 1 and 2 are corequired for activation of atypical protein kinase C and Cbl-dependent phosphatidylinositol 3-kinase during insulin action in immortalized brown adipocytes. | Biochemistry 20041214 |
| Antidiabetic and adipogenic properties in a newly synthesized thiazolidine derivative, FPFS-410. | Metabolism: clinical and experimental 20041201 |
| Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20041201 |
| Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. | Endocrine reviews 20041201 |
| Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. | The Journal of investigative dermatology 20041201 |
| Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. | Diabetologia 20041201 |
| Peroxisome proliferator-activated receptors as attractive antiobesity targets. | Drug news & perspectives 20041201 |
| Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. | Clinical therapeutics 20041201 |
| Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. | Bioinformatics (Oxford, England) 20041122 |
| Synthesis and antihyperglycemic activity profiles of novel thiazolidinedione derivatives. | Bioorganic & medicinal chemistry 20041115 |
| Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041105 |
| Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. | American journal of physiology. Renal physiology 20041101 |
| Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. | Bioorganic & medicinal chemistry letters 20041101 |
| regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. | Diabetes 20041101 |
| Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. | Diabetes care 20041101 |
| Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. | Genes to cells : devoted to molecular & cellular mechanisms 20041101 |
| Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. | Gastroenterology 20041101 |
| An inflammatory cascade leading to hyperresistinemia in humans. | PLoS medicine 20041101 |
| Mechanisms of N-methyl-D-aspartate receptor inhibition by melatonin in the rat striatum. | Journal of neuroendocrinology 20041101 |
| Synthesis and biological activity of benzoxazole containing thiazolidinedione derivatives. | Archives of pharmacal research 20041101 |
| Application of liquid chromatography/mass spectrometry and nuclear magnetic resonance to the identification of degradates of a novel insulin sensitizer in aqueous solutions. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041025 |
| Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. | International journal of cancer 20041020 |
| Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines. | British journal of cancer 20041018 |
| Species differential stereoselective oxidation of a methylsulfide metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor dual agonist. | Drug metabolism and disposition: the biological fate of chemicals 20041001 |
| Integrated genomic and proteomic analyses of gene expression in Mammalian cells. | Molecular & cellular proteomics : MCP 20041001 |
| Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. | British journal of clinical pharmacology 20041001 |
| Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. | Current medical research and opinion 20041001 |
| Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. | Fertility and sterility 20041001 |
| Impaired glucose tolerance is accompanied by decreased insulin sensitivity in tissues of mice implanted with cells that overexpress resistin. | Diabetologia 20041001 |
| Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). | Calcified tissue international 20041001 |
| Pyrazolylborate-zinc alkoxide complexes. 3. Acid-base reactions. | Inorganic chemistry 20040920 |
| Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays. | American journal of physiology. Endocrinology and metabolism 20040901 |
| Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. | Blood 20040901 |
| Second-generation thiazolidinediones and hepatotoxicity. | The Annals of pharmacotherapy 20040901 |
| Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. | Diabetes, obesity & metabolism 20040901 |
| Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. | International journal of oncology 20040901 |
| In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. I. Role of cytochrome P450, methyltransferases, flavin monooxygenases, and esterases. | Drug metabolism and disposition: the biological fate of chemicals 20040901 |
| In vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide], a peroxisome proliferator-activated receptor alpha/gamma agonist. II. Identification of metabolites by liquid chromatography-tandem mass spectrometry. | Drug metabolism and disposition: the biological fate of chemicals 20040901 |
| Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone. | The Journal of clinical endocrinology and metabolism 20040901 |
| Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. | Clinical pharmacology and therapeutics 20040901 |
| Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. | International journal of clinical practice 20040901 |
| Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. | British journal of cancer 20040816 |
| Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. | The Journal of biological chemistry 20040806 |
| Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. | Toxicology in vitro : an international journal published in association with BIBRA 20040801 |
| Alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. | Archives of dermatological research 20040801 |
| Inhibitory effects of multi-substituted benzylidenethiazolidine-2,4-diones on LDL oxidation. | Bioorganic & medicinal chemistry 20040801 |
| C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. | Diabetic medicine : a journal of the British Diabetic Association 20040801 |
| Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20040801 |
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto. | Diabetes care 20040801 |
| Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. | The Journal of clinical endocrinology and metabolism 20040801 |
| Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. | European journal of endocrinology 20040801 |
| Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. | Molecular cancer therapeutics 20040801 |
| Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040801 |
| Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. | Cancer letters 20040728 |
| Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate. | Cancer letters 20040708 |
| A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. | European journal of pharmacology 20040708 |
| Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. | Clinical chemistry 20040701 |
| Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. | Diabetes, obesity & metabolism 20040701 |
| Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. | Free radical biology & medicine 20040701 |
| Improved glycemic control without weight gain using triple therapy in type 2 diabetes. | Diabetes care 20040701 |
| Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. | Diabetologia 20040701 |
| Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting? | Clinical cardiology 20040701 |
| What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? | Clinical cardiology 20040701 |
| [Ameliorations of pioglitazone on insulin resistance in spontaneous IGT-OLETF rats]. | Yao xue xue bao = Acta pharmaceutica Sinica 20040701 |
| Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes. | Drugs of today (Barcelona, Spain : 1998) 20040701 |
| Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. | European journal of pharmacology 20040628 |
| PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. | Circulation research 20040611 |
| Increased adipose tissue expression of Grb14 in several models of insulin resistance. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040601 |
| Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. | Drug metabolism and disposition: the biological fate of chemicals 20040601 |
| Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. | Diabetes care 20040601 |
| Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. | The Journal of clinical endocrinology and metabolism 20040601 |
| Management of the metabolic syndrome. | Minerva endocrinologica 20040601 |
| Quantitative determination of a novel insulin sensitizer and its para-hydroxylated metabolite in human plasma by LC-MS/MS. | Journal of pharmaceutical and biomedical analysis 20040528 |
| Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. | Cancer research 20040515 |
| Coronary vasomotor abnormalities in insulin-resistant individuals. | Annals of internal medicine 20040504 |
| Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. | European journal of pharmacology 20040503 |
| Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. | Diabetologia 20040501 |
| Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. | European journal of medicinal chemistry 20040501 |
| Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. | Clinical therapeutics 20040501 |
| Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. | Biochemical and biophysical research communications 20040423 |
| Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. | Endocrinology 20040401 |
| Annexin II is a thiazolidinedione-responsive gene involved in insulin-induced glucose transporter isoform 4 translocation in 3T3-L1 adipocytes. | Endocrinology 20040401 |
| Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. | Journal of molecular endocrinology 20040401 |
| [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)]. | Nihon rinsho. Japanese journal of clinical medicine 20040401 |
| Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. | The Journal of biological chemistry 20040326 |
| Type 2 diabetes mellitus: what is the optimal treatment regimen? | The American journal of medicine 20040308 |
| Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. | Journal of leukocyte biology 20040301 |
| The metabolic effects of insulin and rosiglitazone combination therapy in Chinese type 2 diabetic patients with nephropathy. | Medical science monitor : international medical journal of experimental and clinical research 20040301 |
| Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. | Drug metabolism and disposition: the biological fate of chemicals 20040301 |
| Increased CD36 protein as a response to defective insulin signaling in macrophages. | The Journal of clinical investigation 20040301 |
| Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. | Clinical pharmacology and therapeutics 20040301 |
| Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. | Clinical therapeutics 20040301 |
| Treatment of metabolic syndrome. | Expert review of cardiovascular therapy 20040301 |
| Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. | The Journal of biological chemistry 20040227 |
| RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040215 |
| Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040215 |
| Identification of a novel mitochondrial protein ('mitoNEET') cross-linked specifically by a thiazolidinedione photoprobe. | American journal of physiology. Endocrinology and metabolism 20040201 |
| PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. | British journal of pharmacology 20040201 |
| Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. | Diabetes 20040201 |
| Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. | Critical care medicine 20040201 |
| Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. | American heart journal 20040201 |
| The metabolic syndrome: an emerging risk state for cardiovascular disease. | Vascular medicine (London, England) 20040201 |
| Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. | The Biochemical journal 20040115 |
| Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats. | Pediatric nephrology (Berlin, Germany) 20040101 |
| Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. | International journal of oncology 20040101 |
| Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. | Diabetes 20040101 |
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. | Diabetes care 20040101 |
| Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist. | Toxicologic pathology 20040101 |
| Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. | The Journal of clinical endocrinology and metabolism 20040101 |
| An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. | Clinical and experimental pharmacology & physiology 20040101 |
| Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. | Current medical research and opinion 20040101 |
| Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective. | PharmacoEconomics 20040101 |
| Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. | Journal of diabetes and its complications 20040101 |
| 15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. | BMC pharmacology 20040101 |
| Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes. | Experimental diabesity research 20040101 |
| Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus. | Clinical laboratory 20040101 |
| Cardiovascular implications of thiazolidinedione therapy. | Progress in cardiovascular nursing 20040101 |
| Tamoxifen and the Rafoxifene analog LY117018: their effects on arachidonic acid release from cells in culture and on prostaglandin I2 production by rat liver cells. | BMC cancer 20040101 |
| Simultaneous determination of MK-0767 and seven metabolites in rat urine using liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20040101 |
| A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. | Breast cancer research : BCR 20040101 |
| Molecular regulation of pancreatic stellate cell function. | Molecular cancer 20040101 |
| Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase. | Redox report : communications in free radical research 20040101 |
| A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches. | Treatments in endocrinology 20040101 |
| Cbl PYXXM motifs activate the P85 subunit of phosphatidylinositol 3-kinase, Crk, atypical protein kinase C, and glucose transport during thiazolidinedione action in 3T3/L1 and human adipocytes. | Biochemistry 20031209 |
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. | Circulation 20031209 |
| The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. | The American journal of medicine 20031208 |
| Beta-cell rejuvenation with thiazolidinediones. | The American journal of medicine 20031208 |
| Thiazolidinedione regulation of smooth muscle cell proliferation. | The American journal of medicine 20031208 |
| Considerations for management of fluid dynamic issues associated with thiazolidinediones. | The American journal of medicine 20031208 |
| Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. | The Journal of pharmacology and experimental therapeutics 20031201 |
| Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. | Current opinion in lipidology 20031201 |
| Muscle-specific Pparg deletion causes insulin resistance. | Nature medicine 20031201 |
| The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. | Atherosclerosis 20031201 |
| Antiedematogenic activity of two thiazolidine derivatives: N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28). | Chemical & pharmaceutical bulletin 20031201 |
| Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. | Laboratory investigation; a journal of technical methods and pathology 20031201 |
| [The effect of peroxisome proliferator-activated receptor alpha and gamma ligands on free fatty acid-induced INS-1 cell impairment]. | Zhonghua nei ke za zhi 20031201 |
| Regulation of cytosolic phosphoenolpyruvate carboxykinase gene expression in adipocytes. | Biochimie 20031201 |
| Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. | Clinical therapeutics 20031201 |
| Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. | Annals of internal medicine 20031104 |
| Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. | Current opinion in cardiology 20031101 |
| Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. | The Journal of clinical endocrinology and metabolism 20031101 |
| Effect of darglitazone on glucose clearance and lipid metabolism in obese cats. | American journal of veterinary research 20031101 |
| Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats. | Canadian journal of physiology and pharmacology 20031101 |
| A phase II trial with rosiglitazone in liposarcoma patients. | British journal of cancer 20031020 |
| Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. | Diabetologia 20031001 |
| Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. | American journal of physiology. Heart and circulatory physiology 20031001 |
| Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. | Developmental cell 20031001 |
| A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. | Biochemical and biophysical research communications 20030919 |
| Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. | The Journal of biological chemistry 20030905 |
| Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. | Biochemical and biophysical research communications 20030905 |
| Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents. | Bioorganic & medicinal chemistry 20030901 |
| Unilateral edema due to a thiazolidinedione. | Diabetes care 20030901 |
| Genomics, transcriptomics, proteomics, and numbers. | Archives of pathology & laboratory medicine 20030901 |
| Diabetes drugs a problem in heart failure. | Harvard heart letter : from Harvard Medical School 20030901 |
| The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study. | Metabolism: clinical and experimental 20030901 |
| Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20030901 |
| Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. | FEBS letters 20030828 |
| Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. | The American journal of cardiology 20030818 |
| Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. | The Journal of biological chemistry 20030815 |
| Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. | The Journal of clinical investigation 20030815 |
| Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. | American journal of physiology. Endocrinology and metabolism 20030801 |
| PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. | The Journal of pharmacology and experimental therapeutics 20030801 |
| Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. | Acta physiologica Scandinavica 20030801 |
| A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. | Metabolism: clinical and experimental 20030801 |
| Benefits of combination therapy of insulin and oral hypoglycemic agents. | Archives of internal medicine 20030801 |
| Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. | The Journal of clinical endocrinology and metabolism 20030801 |
| Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. | The Journal of biological chemistry 20030725 |
| Metformin and thiazolidinedione use in Medicare patients with heart failure. | JAMA 20030702 |
| Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. | European journal of clinical investigation 20030701 |
| [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives]. | Nihon rinsho. Japanese journal of clinical medicine 20030701 |
| Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. | Pharmacotherapy 20030701 |
| Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione insulin sensitizer. | Xenobiotica; the fate of foreign compounds in biological systems 20030701 |
| New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. | Clinical therapeutics 20030701 |
| Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. | Circulation 20030603 |
| Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist. | The Journal of pharmacology and experimental therapeutics 20030601 |
| Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. | Diabetes care 20030601 |
| Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. | Diabetes care 20030601 |
| The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. | The Journal of clinical endocrinology and metabolism 20030601 |
| PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat. | Molecular and cellular endocrinology 20030530 |
| Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. | Circulation 20030527 |
| Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. | The Journal of biological chemistry 20030523 |
| 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists. | Bioorganic & medicinal chemistry letters 20030519 |
| c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. | Biochemical and biophysical research communications 20030502 |
| Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. | Journal of cellular biochemistry 20030501 |
| Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. | Diabetes 20030501 |
| PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. | The Journal of clinical investigation 20030501 |
| A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. | Clinical pharmacology and therapeutics 20030501 |
| Current best treatment for non-alcoholic fatty liver disease. | Expert opinion on pharmacotherapy 20030501 |
| Identification of novel metabolites of pioglitazone in rat and dog. | Xenobiotica; the fate of foreign compounds in biological systems 20030501 |
| Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. | Metabolism: clinical and experimental 20030501 |
| Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. | Postgraduate medicine 20030501 |
| Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. | Circulation 20030422 |
| A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. | European journal of pharmacology 20030418 |
| Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. | Journal of the American College of Cardiology 20030416 |
| Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione- and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats. | Toxicology 20030415 |
| Acute effects of troglitazone and nitric oxide on glucose uptake in L929 fibroblast cells. | Life sciences 20030411 |
| Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. | Diabetes 20030401 |
| Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs? | Expert opinion on investigational drugs 20030401 |
| Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. | The Journal of clinical endocrinology and metabolism 20030401 |
| Resistin: molecular history and prognosis. | Journal of molecular medicine (Berlin, Germany) 20030401 |
| Cholesterol attenuates linoleic acid-induced endothelial cell activation. | Metabolism: clinical and experimental 20030401 |
| Novel biologically based therapies for Waldenstrom's macroglobulinemia. | Seminars in oncology 20030401 |
| Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. | International journal of experimental pathology 20030401 |
| [Prevention of type 2 diabetes: lifestyle changes or pharmacological interventions?]. | Revue medicale de Liege 20030401 |
| Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. | American journal of physiology. Endocrinology and metabolism 20030301 |
| Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030301 |
| Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. | Diabetes care 20030301 |
| Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives. | Chemical & pharmaceutical bulletin 20030301 |
| GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells. | Arteriosclerosis, thrombosis, and vascular biology 20030301 |
| Rosiglitazone: potential beneficial impact on cardiovascular disease. | International journal of clinical practice 20030301 |
| A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. | Diabetologia 20030301 |
| Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. | The Journal of biological chemistry 20030221 |
| A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. | Biochemical and biophysical research communications 20030207 |
| Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. | Chemical & pharmaceutical bulletin 20030201 |
| PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? | International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20030201 |
| Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. | Metabolism: clinical and experimental 20030201 |
| Treatment of insulin resistance in uremia. | The International journal of artificial organs 20030201 |
| Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. | Biochemical and biophysical research communications 20030131 |
| Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. | Biochemical pharmacology 20030115 |
| Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes. | Biochemical and biophysical research communications 20030110 |
| Identification of a stable chymase inhibitor using a pharmacophore-Based database search. | Bioorganic & medicinal chemistry letters 20030106 |
| Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? | The Journal of clinical endocrinology and metabolism 20030101 |
| Vanadyl-thiazolidinedione combination agents for diabetes therapy. | Bioconjugate chemistry 20030101 |
| Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. | The American journal of gastroenterology 20030101 |
| Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. | Arthritis and rheumatism 20030101 |
| Synthesis and hypoglycemic activity of some substituted flavonyl thiazolidinedione derivatives--fifth communication: flavonyl benzyl substituted 2,4-thiazolidinediones. | Farmaco (Societa chimica italiana : 1989) 20030101 |
| Thiazolidinedione inhibition of peritoneal inflammation. | Gynecologic and obstetric investigation 20030101 |
| Continuing education. | Diabetic medicine : a journal of the British Diabetic Association 20030101 |
| Negative growth effects of ciglitazone on kidney interstitial fibroblasts: role of PPAR-gamma. | Kidney & blood pressure research 20030101 |
| Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. | Journal of bone and mineral metabolism 20030101 |
| Current management strategies for coexisting diabetes mellitus and obesity. | Drugs 20030101 |
| Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control? | Current medical research and opinion 20030101 |
| Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). | Cardiovascular diabetology 20030101 |
| Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells. | American journal of nephrology 20030101 |
| [Lipodystrophies: what treatment?]. | Journees annuelles de diabetologie de l'Hotel-Dieu 20030101 |
| Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts--comparison of the effects of pioglitazone and metformin. | Diabetes/metabolism research and reviews 20030101 |
| Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20030101 |
| Nateglinide (Starlix): update on a new antidiabetic agent. | International journal of clinical practice 20030101 |
| Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism. | BMC cancer 20030101 |
| Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. | Diabetes technology & therapeutics 20030101 |
| [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]. | Yakushigaku zasshi 20030101 |
| Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20030101 |
| Potential involvement of the immune system in the development of endometriosis. | Reproductive biology and endocrinology : RB&E 20030101 |
| Peroxisome proliferator-activated receptor-gamma and insulin action: insights from human genetics. | Hormone research 20030101 |
| Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes. | The Diabetes educator 20030101 |
| Therapy for type 2 diabetes. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20030101 |
| Potential roles of ROR-alpha in cardiovascular endocrinology. | Nuclear receptor signaling 20030101 |
| Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. | FEBS letters 20021218 |
| Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. | The Journal of biological chemistry 20021213 |
| 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. | British journal of cancer 20021202 |
| Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. | Endocrinology 20021201 |
| Pioglitazone: effect on CYP3A4 activity. | Journal of clinical pharmacology 20021201 |
| [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)]. | Annales d'endocrinologie 20021201 |
| A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. | Cleveland Clinic journal of medicine 20021201 |
| Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. | Thrombosis research 20021125 |
| Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. | Cancer 20021115 |
| Identification of glutathione conjugates of troglitazone in human hepatocytes. | Chemico-biological interactions 20021110 |
| Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. | Advanced drug delivery reviews 20021105 |
| Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. | Diabetes research and clinical practice 20021101 |
| Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. | Current cardiology reports 20021101 |
| Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. | Nature medicine 20021101 |
| Therapeutic options for the management of type 2 diabetes mellitus. | The American journal of managed care 20021101 |
| [Discovery and development of a new insulin sensitizing agent, pioglitazone]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021101 |
| Oral anti diabetic polychemotherapy in type 2 diabetes mellitus. | Diabetes & metabolism 20021101 |
| The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. | Diabetes 20021001 |
| Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. | Magnetic resonance in medicine 20021001 |
| Seeking sweet relief for diabetes. | Nature biotechnology 20021001 |
| A futile metabolic cycle activated in adipocytes by antidiabetic agents. | Nature medicine 20021001 |
| PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. | The Journal of clinical investigation 20021001 |
| Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives. | Chemical & pharmaceutical bulletin 20021001 |
| Treatment of non-alcoholic steatohepatitis. | Best practice & research. Clinical gastroenterology 20021001 |
| [Combination therapy with biguanides]. | Nihon rinsho. Japanese journal of clinical medicine 20021001 |
| Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20021001 |
| Experimental approaches to study PPAR gamma agonists as antidiabetic drugs. | Methods and findings in experimental and clinical pharmacology 20021001 |
| Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. | Archives of biochemistry and biophysics 20020915 |
| Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system. | Life sciences 20020913 |
| Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. | The American journal of cardiology 20020905 |
| A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. | The American journal of cardiology 20020905 |
| PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. | Diabetes, obesity & metabolism 20020901 |
| Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. | Diabetes care 20020901 |
| Effects of troglitazone on HepG2 viability and mitochondrial function. | Toxicological sciences : an official journal of the Society of Toxicology 20020901 |
| Adipose tissue as a buffer for daily lipid flux. | Diabetologia 20020901 |
| Thiazolidinediones: metabolic actions in vitro. | Diabetologia 20020901 |
| Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. | Urology 20020901 |
| [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
| [Glitazone--a new drug for type 2 diabetes]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
| [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
| [Chemical structures and pharmacological characteristics of novel non-thiazolidinedione insulin sensitizer (JTT-501, FK614)]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
| Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. | The Journal of biological chemistry 20020830 |
| MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. | The Journal of biological chemistry 20020816 |
| Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives. | Bioorganic & medicinal chemistry 20020801 |
| Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis. | Kidney international 20020801 |
| Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats. | Metabolism: clinical and experimental 20020801 |
| Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. | Journal of neurochemistry 20020801 |
| Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs). | Clinical therapeutics 20020801 |
| Biology and toxicology of PPARgamma ligands. | Human & experimental toxicology 20020801 |
| Endothelium, inflammation, and diabetes. | Current diabetes reports 20020801 |
| Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. | Human molecular genetics 20020715 |
| The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. | The Journal of biological chemistry 20020712 |
| Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. | International journal of oncology 20020701 |
| Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. | Toxicological sciences : an official journal of the Society of Toxicology 20020701 |
| Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. | Diabetes 20020701 |
| Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20020701 |
| Peroxisome proliferator-activated receptor-gamma expression in lung. | Chest 20020701 |
| Thiazolidinedione-induced edema. | Pharmacotherapy 20020701 |
| Understanding insulin-resistance in type 2 diabetes. | Journal of the National Medical Association 20020701 |
| Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. | Pharmacology & therapeutics 20020701 |
| The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. | Clinical therapeutics 20020701 |
| Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). | The American journal of cardiology 20020601 |
| Roles of peroxisome proliferator-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. | Current opinion in lipidology 20020601 |
| Genetics and molecular biology: peroxisome proliferator-activated receptor gamma still full of surprises. | Current opinion in lipidology 20020601 |
| The glitazones: a new treatment for type 2 diabetes mellitus. | Intensive & critical care nursing 20020601 |
| T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. | The Journal of biological chemistry 20020531 |
| Mechanisms regulating adipocyte expression of resistin. | The Journal of biological chemistry 20020531 |
| Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. | Circulation 20020514 |
| Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity. | The Journal of biological chemistry 20020510 |
| Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma. | The Journal of biological chemistry 20020510 |
| Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. | Diabetes care 20020501 |
| Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2. | Molecular endocrinology (Baltimore, Md.) 20020501 |
| Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. | The Journal of clinical endocrinology and metabolism 20020501 |
| Induction of adipocyte differentiation by a thiazolidinedione in cultured, subepidermal, fibroblast-like cells of an infant with congenital generalized lipodystrophy. | The Journal of clinical endocrinology and metabolism 20020501 |
| Thiazolidinediones in the treatment of type 2 diabetes. | Expert opinion on pharmacotherapy 20020501 |
| Insulin-sensitising agents: beyond thiazolidinediones. | Expert opinion on emerging drugs 20020501 |
| Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. | British journal of cancer 20020422 |
| Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. | Bioorganic & medicinal chemistry 20020401 |
| Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. | Metabolism: clinical and experimental 20020401 |
| Troglitazone downregulates delta-6 desaturase gene expression in human skeletal muscle cell cultures. | Diabetes 20020401 |
| Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. | Diabetes 20020401 |
| Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. | Kidney international 20020401 |
| A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. | Diabetes care 20020401 |
| Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. | Journal of leukocyte biology 20020401 |
| Polycystic ovary syndrome. Long term sequelae and management. | Minerva ginecologica 20020401 |
| [PPARgamma and insulin resistance]. | Annales d'endocrinologie 20020401 |
| [Oral antidiabetics and lipids]. | Annales d'endocrinologie 20020401 |
| [Is a new therapeutic class justified in the treatment of type 2 diabetes?]. | Annales d'endocrinologie 20020401 |
| Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. | Journal of medicinal chemistry 20020328 |
| Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. | Oncogene 20020328 |
| Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. | Annals of internal medicine 20020319 |
| Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis. | Pancreas 20020301 |
| Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. | Diabetes 20020301 |
| Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. | The Journal of clinical endocrinology and metabolism 20020301 |
| Type 2 diabetes therapy. A pathophysiologically based approach. | Postgraduate medicine 20020301 |
| Biphasic vasodilator action of troglitazone on the renal microcirculation. | Journal of the American Society of Nephrology : JASN 20020201 |
| Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. | Naunyn-Schmiedeberg's archives of pharmacology 20020201 |
| Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. | European journal of pharmacology 20020201 |
| Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. | The Journal of toxicological sciences 20020201 |
| [Polycystic ovary syndrome: treatment with insulin-sensitizing agents]. | Annales d'endocrinologie 20020201 |
| Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity. | The Journal of biological chemistry 20020118 |
| Resistin and obesity-associated insulin resistance. | Trends in endocrinology and metabolism: TEM 20020101 |
| Putative activation of the peroxisome proliferator-activated receptor gamma impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells. | Biology of reproduction 20020101 |
| Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes. | Biochemical pharmacology 20020101 |
| Treatment of type 2 diabetes mellitus: pharmacologic intervention. | The Journal of cardiovascular nursing 20020101 |
| Lipotoxic diseases. | Annual review of medicine 20020101 |
| Diabetes mellitus. Medication update. | Southern medical journal 20020101 |
| [Thiazolidinediones and PPARgamma system in repair of liver damage]. | Recenti progressi in medicina 20020101 |
| A treatment for Mr WP: thiazolidinediones after troglitazone. | Diabetic medicine : a journal of the British Diabetic Association 20020101 |
| Type 2 diabetes management: a comprehensive clinical review of oral medications. | Comprehensive therapy 20020101 |
| Differentiating members of the thiazolidinedione class: a focus on efficacy. | Diabetes/metabolism research and reviews 20020101 |
| Differentiating members of the thiazolidinedione class: a focus on safety. | Diabetes/metabolism research and reviews 20020101 |
| Where thiazolidinediones will fit. | Diabetes/metabolism research and reviews 20020101 |
| Rosiglitazone-induced granulomatous hepatitis. | Journal of clinical gastroenterology 20020101 |
| Novel insulin sensitizers: pharmacogenomic aspects. | Pharmacogenomics 20020101 |
| Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. | Diabetes/metabolism research and reviews 20020101 |
| PPAR(gamma) and glucose homeostasis. | Annual review of nutrition 20020101 |
| Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes? | Diabetes technology & therapeutics 20020101 |
| Metabolic and additional vascular effects of thiazolidinediones. | Drugs 20020101 |
| Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. | Drugs 20020101 |
| [Changes in carbohydrate metabolism in the HIV/AIDS patient]. | Nutricion hospitalaria 20020101 |
| Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer cells. | Oncology reports 20020101 |
| Glitazones: clinical effects and molecular mechanisms. | Annals of medicine 20020101 |
| Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101 |
| Thiazolidinedione therapy in a patient with diabetes after cardiac transplantation. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101 |
| Oral combination therapy for type 2 diabetes. | Diabetes/metabolism research and reviews 20020101 |
| Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats. | European journal of drug metabolism and pharmacokinetics 20020101 |
| Management of rosiglitazone-induced edema: two case reports and a review of the literature. | Diabetes technology & therapeutics 20020101 |
| Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. | Current medical research and opinion 20020101 |
| Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20020101 |
| Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20020101 |
| Effects of the thiazolidinediones on cardiovascular risk factors. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Treatment of nonalcoholic fatty liver disease. | Annals of hepatology 20020101 |
| The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. | Treatments in endocrinology 20020101 |
| Potential utility of insulin sensitizers in the treatment of patients with Polycystic ovary syndrome. | Treatments in endocrinology 20020101 |
| Spotlight on rosiglitazone in the management of type 2 diabetes mellitus. | Treatments in endocrinology 20020101 |
| Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. | The Journal of biological chemistry 20011221 |
| Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. | Diabetes research and clinical practice 20011201 |
| Dehydroepiandrosterone alters phospholipid profiles in Zucker rat muscle tissue. | Lipids 20011201 |
| Insulinotropic meglitinide analogues. | Lancet (London, England) 20011117 |
| [Insulin sensitizer drugs, thiazolidinediones: current state and prospect]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [A role of the PPAR gamma activation in insulin resistance]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [Development of new antidiabetic drugs through the advanced knowledge of molecular biology in insulin signal transduction]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [Pharmacological effects of a thiazolidinedione derivative, pioglitazone]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [Evaluation of a thiazolidinedione compound as a new antidiabetic drug]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [Clinical difference between thiazolidinediones and biguanides]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [Evaluation of thiazolidinedione derivative drugs for safety]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| [Clinical usefulness of combination treatment with thiazolidinedione and insulin]. | Nihon rinsho. Japanese journal of clinical medicine 20011101 |
| PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. | International journal of cancer 20011101 |
| Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. | Journal of internal medicine 20011101 |
| [Type 2 diabetes. Regulating insulin according to need]. | MMW Fortschritte der Medizin 20011018 |
| Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. | Biochemical pharmacology 20011015 |
| Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. | Toxicology 20011005 |
| Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression. | Diabetes 20011001 |
| Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. | Diabetes 20011001 |
| Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20011001 |
| Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione. | Chest 20011001 |
| Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors. | Prostaglandins, leukotrienes, and essential fatty acids 20011001 |
| A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. | Biochimie 20011001 |
| TNFalpha inhibits insulin's antiapoptotic signaling in vascular smooth muscle cells. | Biochemical and biophysical research communications 20010928 |
| Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. | Biochemical and biophysical research communications 20010928 |
| Galectin-12, an Adipose-expressed Galectin-like Molecule Possessing Apoptosis-inducing Activity. | The Journal of biological chemistry 20010907 |
| Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2). | The Journal of biological chemistry 20010907 |
| A review of rosiglitazone in type 2 diabetes mellitus. | Pharmacotherapy 20010901 |
| Postoperative management of the diabetic patient. | The Medical clinics of North America 20010901 |
| Pharmacokinetics and clinical efficacy of pioglitazone. | International journal of clinical practice. Supplement 20010901 |
| Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. | Archives of toxicology 20010901 |
| [News in oral antidiabetic therapy]. | Vnitrni lekarstvi 20010901 |
| Liver enzyme monitoring in patients treated with troglitazone. | JAMA 20010815 |
| Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. | Cancer research 20010815 |
| [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents]. | Nederlands tijdschrift voor geneeskunde 20010811 |
| The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. | Nature medicine 20010801 |
| Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. | Chemical research in toxicology 20010801 |
| Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s). | The American journal of the medical sciences 20010801 |
| Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? | Journal of cardiovascular risk 20010801 |
| Pharmacological treatment of insulin resistance in obesity. | Nutrition, metabolism, and cardiovascular diseases : NMCD 20010801 |
| [Thiazolidinediones--a new class of oral antidiabetic drugs]. | Orvosi hetilap 20010722 |
| Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. | The Journal of biological chemistry 20010706 |
| Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse. | European journal of endocrinology 20010701 |
| A new era in type 2 diabetes mellitus treatment? | The American journal of medicine 20010701 |
| Case of the month. Hepatic and renal failure in a patient taking troglitazone and metformin. | The Journal of the Arkansas Medical Society 20010701 |
| Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially reversed by 2,4-thiazolidinedione. | Domestic animal endocrinology 20010701 |
| Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. | European journal of pharmacology 20010629 |
| Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes. | European journal of pharmacology 20010622 |
| Lessons from the glitazones: a story of drug development. | Lancet (London, England) 20010609 |
| Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. | International journal of cancer 20010601 |
| Insulin and glucocorticoids differentially regulate leptin transcription and secretion in brown adipocytes. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010601 |
| Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. | British journal of cancer 20010601 |
| Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat. | Diabetes, obesity & metabolism 20010601 |
| Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. | American journal of respiratory cell and molecular biology 20010601 |
| Type 2 diabetes. How new insights, new drugs are changing clinical practice. | Geriatrics 20010601 |
| Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase. | The Journal of biological chemistry 20010518 |
| Troglitazone induces GLUT4 translocation in L6 myotubes. | Diabetes 20010501 |
| Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. | Diabetes 20010501 |
| Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010501 |
| The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. | Diabetes care 20010501 |
| Oral agents in the management of type 2 diabetes mellitus. | American family physician 20010501 |
| [Current and future aspects of oral antidiabetic agents in type 2 diabetes]. | Vnitrni lekarstvi 20010501 |
| [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010501 |
| MCC-555 (Mitsubishi-Tokyo Pharmaceuticals). | IDrugs : the investigational drugs journal 20010501 |
| New oxadiazolidinedione derivatives as potent and selective human beta3 agonists. | Bioorganic & medicinal chemistry letters 20010423 |
| Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. | The Journal of biological chemistry 20010420 |
| Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. | The Journal of clinical endocrinology and metabolism 20010401 |
| Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. | The American journal of managed care 20010401 |
| [Glitazones. Profile of a new class of substances]. | Der Internist 20010401 |
| Obesity and free fatty acids: double trouble. | Nutrition, metabolism, and cardiovascular diseases : NMCD 20010401 |
| Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. | Diabetic medicine : a journal of the British Diabetic Association 20010401 |
| [Study on 3D-QSAR of PPAR gamma agonists with thiazolidinedione and arylketo-acid moieties]. | Yao xue xue bao = Acta pharmaceutica Sinica 20010401 |
| 2,4-Thiazolidinediones as potent and selective human beta3 agonists. | Bioorganic & medicinal chemistry letters 20010326 |
| The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells. | Molecular pharmacology 20010301 |
| Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. | Molecular pharmacology 20010301 |
| Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. | Arteriosclerosis, thrombosis, and vascular biology 20010301 |
| Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. | Diabetes 20010301 |
| Inhibitory effect of troglitazone on glucuronidation catalyzed by human uridine diphosphate-glucuronosyltransferase 1A6. | European journal of clinical pharmacology 20010301 |
| Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione. | Pharmacotherapy 20010201 |
| Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. | Diabetes care 20010201 |
| Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. | Naunyn-Schmiedeberg's archives of pharmacology 20010201 |
| A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. | The American journal of gastroenterology 20010201 |
| [Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)]. | Arzneimittel-Forschung 20010201 |
| [Significance of PPAR gamma (peroxisome proliferator-activated receptor gamma) in atherosclerosis]. | Nihon rinsho. Japanese journal of clinical medicine 20010201 |
| PPAR gamma: an essential role in metabolic control. | Nutrition, metabolism, and cardiovascular diseases : NMCD 20010201 |
| The chlorophyll metabolite phytanic acid is a natural rexinoid--potential for treatment and prevention of diabetes. | Medical hypotheses 20010201 |
| Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. | Chemical research in toxicology 20010101 |
| Thiazolidinedione- and tumor necrosis factor alpha-induced downregulation of peroxisome proliferator-activated receptor gamma mRNA in differentiated 3T3-L1 adipocytes. | Metabolism: clinical and experimental 20010101 |
| Insulin resistance and its treatment by thiazolidinediones. | Recent progress in hormone research 20010101 |
| Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101 |
| Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. | The Annals of pharmacotherapy 20010101 |
| Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents. | European journal of medicinal chemistry 20010101 |
| Hepatotoxicity with thiazolidinediones: is it a class effect? | Drug safety 20010101 |
| Structure toxicity relationships--how useful are they in predicting toxicities of new drugs? | Advances in experimental medicine and biology 20010101 |
| [Drug interactions as exemplified by thiazolidinediones (glitazones). Commentary on the publication of Ulrich Klotz and Dietmar Sailer, 'Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)'Arzneimittelforschung. 2001 Feb;51(2):112-7]. | Arzneimittel-Forschung 20010101 |
Related Products
© 2019 Angene International Limited. All rights Reserved.